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1. INTRODUCTION 
The resistance offered by a microbe to an antimicrobial agent that is used in the 
prevention or treatment of infections caused by it is called antimicrobial resistance.1 
According to WHO, Antimicrobial resistance of an organism is said to have 
developed in an organism, if the organism becomes resistant to a drug to which it had 
earlier showed susceptibility.2 Resistance is the characteristic of a microbe, and does 
not characterise any person.1 
The most important cause of Antimicrobial resistance is injudicious use of 
antibiotics, mainly due to easy availability, especially over the counter.3But bacteria 
with antimicrobial resistance were found even before antibiotics were used.4 Poor 
compliance of the patient to antibiotic regimen, insufficient infection control methods, 
unclean sanitary practices and food handling which is inappropriate add fuel to the 
fire. Other causes of emergence of resistance to drugs are increased use of antibiotics 
in livestock feed in many countries5, inadequate treatment of waste water released 
from pharmaceutical manufacturers and release of large quantities of antibiotics into 
the environment.6 
β-lactams, containing the β-lactam ring, are the antibiotics which are most 
commonly used to treat infections caused by gram negative bacteria.  
Figure 1 Structure of β-lactam antibiotic 
 
These antibiotics act on the cell wall and inhibit cell wall synthesis by blocking the 
transpeptidase enzyme.7 
Among the β-lactam antibiotics, there are various classes depending upon the 
nature of the heteroatom included in the cycle – Penicillins, Cephalosporins, 
Monobactams and Carbapenems.7 Of these, the Carbapenems are the drugs of last 
resort which are used in treating Multidrug resistant infections unresponsive to 
treatment with the other classes of β-lactam antibiotics. 8 
Enterobacteriaceae are gram negative human pathogens causing various 
community acquired and hospital acquired infections like fever, blood stream 
infections, urinary tract infections, infections of lung, abdomen, CNS and device-
associated infections.8They can easily spread between humans through contaminated 
hand, water and food. Transposons and plasmids mediate transfer of genes 
horizontally.8 
Community-acquired Enterobacteriaceae isolates producing Extended-
spectrum betalactamases are spreading and have been reported worldwide.8 β-lactams 
with inhibitor combinations are being increasingly used in the treatment of such 
bacterial infections.9But organisms resistant even to these combinations have 
dramatically increased. Carbapenems were used to treat such organisms. Recently, 
organisms resistant even to Carbapenems are on the rise. 
 In the recent past, Carbapenem-resistant Enterobacteriaceae are being 
identified and brought to light in all countries across the world principally because of 
acquirement of genes that are responsible for Carbapenemase production. 
The Carbapenemases are betalactamases that are capable of inactivating or 
hydrolysing the Carbapenem group of betalactam antibiotics. This is the main cause of 
Carbapenem resistance in gram negative bacilli.10 Hyperproduction of enzymes called 
Amp C betalactamases can also result in resistance to Carbapenems.10 
The Carbapenemases, by hydrolysing or inactivating Carbapenems have 
deprived us of the last choice of antibiotics, the Carbapenems, there by posing a 
serious threat to the patient and the physician by increasing morbidity and mortality 
due to infections with Multi-drug resistant (MDR) organisms8. 
β-lactamases are classified in molecular and functional ways as described by 
Ambler’s and Bush Jacoby classifications respectively11. Of these, the Metalloβ-
lactamases and Carbapenemases are the newly discovered β-lactamases.12The 
Carbapenemases have been broadly classified into Serine Carbapenemases and 
Metalloβ-lactamases based on the reactive sites of the enzymes.10 
The classes of Carbapenemases with examples have been depicted in the table 
below. 
Table 1 Classification of Carbapenemases10 
Class of Carbapenemase Active site ingredient Examples 
Class A Serine KPC, NMC,GES,IMI, SME 
Class B Metal ion(Zinc) IMP, NDM, VIM 
Class D Serine OXA 48, OXA 53 
 
Carbapenemases have been increasingly reported in bacteria of the 
Enterobacteriaceae family8. These drug resistant organisms pose a real challenge to 
the patient and the treating physician. The former has to face the toxic effects of the 
drugs if higher doses are needed. The later has to face a challenge in choosing an 
alternative drug to treat the patient and to get a successful outcome. 
Finding out patients and the carriers colonised/infected with 
Enterobacteriaceace that produce Carbapenemases can help to a great extent in 
preventing further spread of these resistant organisms. A special emphasis has been 
given to Enterobacteriaceae because they are the most common organisms causing 
community acquired and nosocomial infections.8 
  Carbapenemases produced by the resistant bacteria can be detected by various 
phenotypic tests and confirmed by genotyping. 
Ours is a tertiary care seven hundred and seventy bedded hospital attached to medical 
college catering mostly to rural population with an out-patient turnover of around 
thousand three hundred patients per day. 
Our aim was to detect the prevalence of Carbapenemase producing strains 
among the Carbapenem resistant Enterobacteriaceae. This type of study has not been 
done in this area, which is predominantly a rural population and that is the reason why 
this study was undertaken. 
 
 
 
 
 
 
2. AIMS AND OBJECTIVES 
 To detect the prevalence of Carbapenemase producers among the Carbapenem 
resistant Enterobacteriaceae using various phenotypic methods. 
 Molecular detection of blaNDM-1 and blaOXA-51 genes among the 
Carbapenemase producers. 
 To compare various phenotypic and genotypic methods and to determine the 
efficacy of each phenotypic test. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. REVIEW OF LITERATURE 
3.1 HISTORICAL PERSPECTIVES OF ENTEROBACTERIACEAE: 
Enterobacteriaceae are gram negative bacilli that inhabit the intestines of 
humans and animals and are called “Enteric bacteria” or “Enterobacteria”. Otto Rahn 
first proposed the name Enterobacteriaceae in 1937 for a group of organisms which 
were similar in their morphological and biochemical aspects, within a single genus 
called Enterobacter.13 
Borman, Stuart and Wheeler (1944) defined the family as gram negative bacilli 
that were non sporing and widely distributed in nature, fermenting glucose forming 
acid alone or acid with gas, reduce nitrates to nitrites. When motile the flagella are 
peritrichous.14 
The scientific classification of Enterobacteriaceae is as follows. 
Table 2 Scientific classification of Enterobacteriaceae13 
Domain Bacteria 
Phylum Proteobacteria 
Class Gammaproteobacteria 
Order Enterobacteriales 
Family Enterobacteriaceae 
 
Members of Enterobacteriaceae reside in the intestine of humans and animals and 
other mammalian hosts as symbionts and commensals. They have the capacity to 
synthesize vitamin K, which cannot be synthesised by their hosts by themselves. 
However, some of them may become pathogenic, causing diseases like gastroenteritis 
and urinary tract infections14. 
3.2 DISCOVERY OF THE MEMBERS OF ENTEROBACTERIACEAE: 
Serratia was the first member of Enterobacteriaceae to be discovered in 1819 
by Bizio on an Italian dish. Subsequently other members were discovered.14 
Table 3 Discovery of the members of Enterobacteriaceae14 
Member (Genus) Year of discovery Name of the discoverer 
Serratia 1819 Bartolomeo 
Providencia 1852 Robert Bowley 
Klebsiella 1882 Carl Friedlander 
E.coli 1885 Theodore Escherich 
Salmonella 1885 Daniel E Salmon 
Proteus 1885 Gustav Hauser 
Yersinia pestis 1894 Alexandre Yersin 
Shigella 1896 Kiyoshi Shiga 
Morganella 1906 Morgan 
Citrobacter 1932 Werkman and Gillen 
Enterobacter 1960 Hormache & Edwards 
Edwardsiella 1962 Frank 
 
3.3 CLASSIFICATION OF ENTEROBACTERIACEAE: 
 Members of Enterobacteriaceae were first classified in 1893 by Theobald 
Smith into Lactose fermenters and lactose nonfermenters. Ability to ferment 
lactose distinguishes enteric from obligate aerobes and is of practical value in 
diagnostic microbiology.14 Lactose fermenters include Escherichia, 
Enterobacter, Citrobacter and Klebsiella. Non lactose fermenters are 
Salmonella , Shigella, Yersinia and Proteus.14 
 Cowan in 1956 classified Enterobacteriaceae into six genera: Salmonella, 
Escherichia, Shigella, Citrobacter, Klebsiella and Proteus15 
 Ewing (1960,1966) classified Enterobacteriaceae into four tribes: 
Escherichiae, Klebsiellae,  Proteeae and Erwiniae.16 
  The three widely used systems for the classification of Enterobacteriaceae are 
Bergey’s, Kauffmann and Edwards-Ewing. They have certain differences, but 
their general approach is the same.16 
Table 4 Edwards-Ewing classification of Enterobacteriaceae16 
Tribe I.Escherichiae II.Klebsielleae III.Proteeae IV.Erwinieae 
 
Genus 1.Escherichia 
2.Edwardsiella 
3.Citrobacter 
4. Salmonella           
5. Shigella 
1.Klebsiella    
2.Enterobacter 
3.Hafnia 
4.Serratia 
 
1.Proteus 
2.Morganella 
3.Providencia 
 
1.Erwinia 
 
 Between 1950s and 1970s, methods like chemotaxonomy, Carbon utilization 
assay and phage typing were used for classification and identification.18 
 DNA hybridization was pioneered by Don Brenner at CDC in early 1970s as 
the gold standard for determining relatedness among bacteria. 18 
 Currently 16sRNA sequencing is being widely used to identify and classify 
Enterobacteriaceae and bacteria which could not be done by conventional 
methods.18 
3.4 PROPOSED CHANGES IN ENTEROBACTERIACEAE:  
 Based on 16 S rRNA studies, Plesiomonas was found to be more related to 
Enterobacteriaceae than to Vibrionaceae family and so it has been 
classified into Enterobacteriaceae family.18 
 Three species of Klebsiella that has been assigned to Raoultella are 
K.ornitholytica, K.terrigena, K.planticola.19 
 Calymmatobacterium granulomatis has been assigned to Klebsiella family19 
 Enterobacter sakazakii was identified as a new species in 1980. 19 
 
3.5 ENTEROBACTERIACEAE AND INFECTION: 
Enterobacteriaceae is the most medically important bacterial family which 
includes bacteria capable of causing infections in large numbers in community as well 
as in hospitals. They are associated with infections involving the gastrointestinal, 
urinary tract, skin and soft tissues, wound, meninges and blood stream20. 
 
3.5.1 CLINICAL MANIFESTATIONS OF ENTEROBACTERIACEAE 
INFECTIONS: 
The coliform bacilli (genera Escherichia, Enterobacter, Klebsiella, 
Serratia, Proteus and Citrobacter) are potential pathogens that can cause a number of 
infections. Escherichia coli is the member of Enterobacteriaceae that is most 
commonly isolated in the clinical laboratory.21The infections caused by the bacteria 
belonging to Enterobacteriaceae are as follows. 
 
 Enteric Infections: In developing countries, the most common enteric 
pathogen is E.coli. The enteric pathogens include, classical enteropathogenic, 
enterotoxigenic, enterohemorrhagic, enteroinvasive and enteroggregative 
strains.21 
 Nosocomial Infections: Around 30 percent of HAIs in United States is due to 
Coliform and Proteus bacilli. The major sites of hospital acquired infections are 
the urinary tract, bloodstream, lung (pneumonias) and surgical sites. These 
nosocomial pathogens are responsible for more than 40% of the urinary tract 
and more than 20% of surgical site infections. They also contribute to more 
than 15% of the blood stream infections and about 30% of the lung 
infections. E coli is the most common pathogenic cause of hospital acquired 
infections.21 
 Community-Acquired Infections: Most cases of UTI are caused by 
Escherichia coli. Other members of Enterobacteriaceae associated with UTI 
are Klebsiella, Proteus and Enterobacter species. Proteus mirabilis is the most 
common cause of complicated urinary tract infections. K.pneumoniae, 
K.ozaenae and  K.rhinoscleromatis cause pneumonia, ozena and rhinoscleroma 
respectively.21 
 
 
 
 
 
 3.6 TREATMENT OPTIONS FOR ENTEROBACTERIACEAE INFECTIONS: 
 Common antibiotics used for Gram negative bacterial infections are 
Betalactams, Aminoglycosides, Macrolides and Fluoroquinolones.22 
 
Table 5 Treatment options for Enterobacteriaceae infections 
Organism Clinical condition and drugs used in treatment 
E.coli Cystitis – Fluoroquinolones or nitrofurantoin 
Meningitis- Ceftriaxone 
Pneumonia- 3rd gen Cephalosporins or Fluoroquinolones 
Cholecystitis – Third gen cephalosporins 
Intra abdominal abscess- piperacillin-tazobactam, imipenem, 
cilastatin23 
Klebsiella UTI – oral quinolones, third gen cephalosporins 
Community acquired pneumonia – third gen cephalosporins and 
quinolones 
Nosocomial pneumonia – Aminoglycosides in addition to the above 
mentioned drugs24 
Proteus Uncomplicated UTI – Quinolones or Cotrimoxazole 
Complicated UTI – Ceftriaxone, Gentamycin, Cotrimoxazole, 
Aztreonam25 
Enterobacter Betalactams, Carbapenems, Fluoroquinolones, Aminoglycosides 26 
 
 
 
 
 
 3.7 BETALACTAM ANTIBIOTICS: 
3.7.1 STRUCTURE AND ACTION OF BETALACTAMS: 
 Betalactam antibiotics are a class of antibiotics containing the betalactam ring. 
The betalactam ring is a four membered cyclic amide consisting of three carbon 
(3 C) atoms and one nitrogen (1 N) atom. It is named so because of the 
attachment of Nitrogen atom to the β-carbon in relation to the Carbonyl (C=O) 
group.7 
 Betalactam antibiotics include Penicillins, Cephalosporins, Monobactams and 
Carbapenems7. 
 Betalactam antibiotics are cell wall precursor analogues, which act by binding 
with PBPs (Penicillin binding Proteins) in bacterial cell wall and inhibiting new 
cell wall peptidoglycan synthesis mediated by the transpeptidase enzyme.7 
Furthermore, binding of betalactam drugs to PBP triggers the cell wall 
hydrolases, which cause lysis of bacterial cell wall7. 
 
3.8 EVOLUTION OF DRUG RESISTANCE IN ENTEROBACTERIACEAE: 
The ability of the bacteria to survive and multiply withstanding the effect of 
antibiotic is termed as antibiotic resistance.27 E.coli is the organism from which the 
first betalactamase was detected, even before penicillin came into use in medical 
practice27. 
 
 
Table 6 Evolution of drug resistance in Enterobacteriaceae 
Year Event (Antimicrobial resistance) 
1937 Sulfonamides introduced for treatment28 
1940 Penicillin came into clinical use29 
1940 First evidence of betalactamases (Penicillinase) 
demonstrated in E.coli by Abraham and Chain29 
1940 Tetracycline came into clinical use30 
1953 First tetracycline resistance was reported in Shigella 
dysentriae30 
1970s Plasmid mediated β-lactamases assumed importance in 
Enterobacteriaceae and other gram negative bacteria31 
1972 First epidemic of Chloramphenicol resistant Salmonella in 
Kerala reported by Paniker et al.32 
1989 MDR S.Typhi outbreaks resistant to Chloramphenicol, 
Ampicillin, Trimethoprim, Streptomycin, Tetracycline and 
Sulfonamides were reported in India and Pakistan32 
1992 S.Typhi resistant to Ciprofloxacin was first reported in 
UK.32 
1970-80s Development of broad spectrum Cephalosporins, 
Cephamycins, Monobactams and Carbapenems29 
1990 Inducible chromosomally mediated β-lactamases among 
gram negative bacteria29 
 
E.coli resistance to the antibiotic of last resort – colistin has now been reported 
in US (2016)33.The increasing resistance among these organisms are indicative of 
changes in the frequency of antibiotic resistance determining genes.34 
3.9 CARBAPENEM RESISTANT ENTEROBACTERIACEAE (CRE): 
Enterobacteriaceae resistant to treatment with Carbapenems are called 
Carbapenem resistant Enterobacteriaceae. They are difficult to treat organisms 
because of their high resistance, even to the last resort antibiotics – The 
Carbapenems.35 Klebsiella and E.coli are the most commonly encountered CRE.35 The 
two mechanisms of resistance in CRE are Carbapenemases (Βetalactamases that 
hydrolyse Carbapenems) and Cephalosporinases along with porin loss.10Klebsiella 
pneumoniae Carbapenemase (KPC), NDM (New Delhi Metallo-betalactamase) and 
VIM (Verona Integron-Mediated Metallo-β-lactamase) are some of the 
Carbapenemases.10 
3.10 TYPES OF DRUG RESISTANCE: 
 Drug resistance can be genetic or non genetic. The genetic drug resistance can 
be chromosomal or extra chromosomal according to the location of resistance 
determining gene. 27 
  Mutations in such genes coding antibiotic target site proteins cause 
chromosomal resistance.27 Thus alteration in the penicillin binding proteins 
(PBPs) result in resistance to betalactam antibiotics. These resistant genes are 
transferred to the bacterial progeny during replication, but not transferable from 
one species to the other. 27 
 Plasmids and transposons are extra chromosomal mobile genetic elements 
which can carry resistant genes for antibiotics, for example plasmid genes 
encoding β-lactamases. In contrast to chromosomal genes, extra chromosomal 
genes are transferable by conjugation, transformation and transduction.27  
3.11 MECHANISMS OF ANTIBIOTIC RESISTANCE IN GRAM NEGATIVE 
BACILLI: 
Antimicrobial resistance by a microbe can occur through any of the following 
mechanisms.27  
 Inactivation of the antibiotic by enzyme production (Example. Betalactamase 
enzyme production) - the commonest mechanism of resistance. 
  Target site alteration such that the binding capacity of the antibiotic is reduced. 
(Example. Production of new Penicillin Binding Proteins) 
  Modification of metabolic pathways,  
 Active efflux pumps that throw away the antibiotic out of the cell resulting in  
reduced intracellular concentration of the drug.27 
 
3.12 ΒETALACTAMASES: 
Enzymes which inactivate betalactam antibiotics by hydrolyzing the nitrogen-
carbonyl bond in their betalactam ring are collectively known as betalactamases. They 
can be plasmid mediated or chromosomal.7These β-lactamases are secreted as 
exozymes in gram positive bacteria and within the periplasmic space in bacteria that 
are gram negative.7 
 
3.12.1 CLASSIFICATION OF ΒETALACTAMASES: 
There are two popular classifications for betalactamases - Bush Jacoby 
Medeiros functional classification and Ambler’s molecular classification.7  
 
3.12.1.1 AMBLER’S MOLECULAR CLASSIFICATION  
This system categorizes all betalactamases into four classes (A-D) based on 
protein homology (nucleotide and amino acid sequence) instead of phenotypic 
characters. Enzymes of Classes A, D and C have serine at their active site and are 
called serine betalactamases. In contrast, class B enzymes require zinc for their 
activity and hence known as Metallo-betalactamases. ESBL enzymes belong to 
Ambler class A and D12. 
 Class A: Large proteins (MW 29,000), common in GNB, preferentially 
hydrolyse penicillins, e.g. TEM-112 
 Class B: Metalloenzymes (require zinc), common in P. aeruginosa, 
Acinetobacter spp., not inhibited by clavulanic acid but chelation with zinc 
renders it inactive. 12  
 Class C: Cephalosporinase activity, has structural homology with PBPs, large 
proteins (MW 39,000), e.g. AmpC of E. Coli.12 
 Class D: Hydrolyse oxacillin, plasmid mediated e.g. OXA-1.12  
Figure 2 Ambler’s molecular classification of β-lactamases12 
BETALACTAMASES 
Ambler’s molecular classification of Betalactamases 
B D C A 
SERINE ENZYMES METALLO ENZYMES 
3.12.1.2 BUSH-JACOBY-MEDEIROS FUNCTIONAL CLASSIFICATION11 
Table 7 Bush-Jacoby-Medeiros classification scheme for betalactamases with 
corresponding Ambler classes 
 
Location of betalactamase gene on † bacterial chromosome; *plasmid; ‡ transposon 
§ Serine Carbapenemase; ұ Zinc based Carbapenemase also known as metallo 
betalactamase 
It was introduced by Bush Jacoby and Medeiros in 1995. It is based on substrate and 
inhibitor profile. Since it takes into consideration the interaction between betalactam 
drugs and betalactamase inhibitors with these enzymes, it is more relevant to a 
Bush-
Jacoby 
Group 
Sub 
groups Enzyme type 
Molecular 
Class 
No.  of 
enzymes 
Clavulanate 
inhibition Examples 
1 --- 
Cephalosporinase
†* C 53 no E.cloacae 
2 2a Penicillinase*‡ A 20 yes S.aureus, S.albus 
 2b 
Broad 
Spectrum†* A 16 yes TEM-1,SHV-1 
 2be 
Extended 
Spectrum* A 38 yes TEM-3,SHV-2 
 2br 
Inhibitor 
Resistant A 9 Diminished TEM-30,TRC-1 
 2c Carbenicillinase A 15 Yes 
PSE-1,CARB-
3,BRO-1 
 2d Cloxacilliase Dor A 18 Yes 
 2e Cephalosporinase A 19 Yes Proteus 
 
2f Carbapenemase § A 3 Yes E.clocae IMI-1. NMC-
A 
3 --- Metalloenzyme ұ B 15 No S.maltophila L1 
4 --- Penicillinase  7 No P. cepacia 
physician or microbiologist11. 
The current system includes classes C, A and D betalactamases which belong to 
functional group 1,2 and 3 respectively.11 
 
3.13 CARBAPENEMASES: 
Carbapenemases are betalactamases that cause resistance to the Carbapenems, 
the β-lactam group with the broadest spectrum of antibacterial action. Carbapenems 
were less susceptible to the inactivating activity of many betalactamases till the recent 
past. But now even these efficient antibiotics are becoming susceptible to the 
enzymatic inactivation by betalactamases.10 
The enzymes hydrolysing Carbapenems can be grouped into classes A or B by 
molecular analysis. The former has serine as the active site member and the latter has 
zinc at the active site.10 since these enzymes are dependent on zinc, a metal, they are 
called Metallobetalactamases.10Some class C Cephalosporinases can hydrolyse/ 
inactivate Carbapenems and result in Carbapenem resistane, but they are not called 
Carbapenemases because they are not Carbapenem specific.10 
 
3.14 NATURAL OCCURRENCE OF CARBAPENEMASES: 
In 1993, the first Carbapenemase producing Enterobacteriaceae (NmcA) 
identified was Enterobacter,10 following which, a number of types of Carbapenemases 
have been identified. Carbapenemase producers in general produce more than one 
type of betalactamase, making them resistant to many other groups of antibiotics in 
addition to Carbapenems.10 Two class A enzymes in Enterobacter cloacae isolates and 
four class A enzymes from Serratia marscescens isolates were identified.10 Serine 
Carbapenemase producers were found to produce class C Cephalosporinases in 
addition to that. Therefore group 2f enzymes were called as “secondary β-lactamases,” 
by Livermore.10 
Metalloenzymes that were mediated through plasmids were identified from 
Japan, after the description of chromosome mediated enzymes, before the last decade 
of the twentieth century.10All gram negative bacteria, including the 
Enterobacteriaceae and Non fermenters were found to produce these enzymes. 
Carbapenem mediated increased selection pressure can result in the spread of these 
plasmid mediated Metallobetalactamases much faster than one could predict.10 
 
3.15 EPIDEMIOLOGY OF CARBAPENEMASES:  
 International travel increases the chance of infection/colonisation with 
antibiotic-resistant organisms with a higher risk for people travelling to India, the 
Middle East and Africa10. Klebsiella pneumoniae Carbapenemases (KPC) were 
initially reported in United States in various members of Enterobacteriaceae, 
following which they were reported in other countries like India, China and all 
over the world at later stages.10 
Bacterial isolates producing Guiana extended spectrum (GES) Carbapenemases 
have been reported all over the world, after having been initially reported in 
European and Asian countries. However, this enzyme is comparatively rare.10 
Verona integron mediated (VIM-1) Carbapenemases and Imipenem 
hydrolysing betalactamases (IMI-1) have been reported mainly from Asian, 
African and European countries and also across the world. Sao Paulo 
Metalloenzymes (SPM) were detected in Brazil initially and they still remain 
confined to Brazil. Seoul imipenemase and German imipenemase enzymes are 
also confined to the places where they originated.10 
Verona integron mediated enzymes were the most frequently isolated 
Metalloenzymes till New Delhi Metallobetalactamases (NDM) took hold of that 
place in 2008, when the first NDM producing isolate was detected in a patient in 
Sweden who was originally from India. 10 From 2009, there has been a substantial 
increase in the incidence and detection of New Delhi Metallobetalactamases from 
all over the world. Since blaNDM-1 gene is located on a genetic element which is 
highly mobile, it can spread easily, which has resulted in rapid spread of the same 
gene from Asian countries like India to the United States and all over the world, 
probably due to medical tourism. Hospitalisation in India has been proposed to be 
a major determinant in acquiring NDM genes.10 
Oxacillinases capable of hydrolysing Carbapenems are mainly confined to Non 
fermenters like Acinetobacter baumanii. But there are reports of oxacillinases 
being isolated from Enterobacteriaceae isolates like Klebsiella pneumoniae from 
Asian and American countries. Some of the oxacillinases are OXA-58, OXA-48, 
OXA-51 and OXA-23.10 
Thus drug resistant Enterobacteriaceae are widely spread throughout the 
world, with NDM being predominant in India.10 
 
 
3.16 PRODUCTION OF CARBAPENEMASES: 
There can be numerous patterns for the production of several betalactam 
hydrolysing enzymes. MBL gene expression may be inducible or may not be 
inducible.  
 Class A Carbapenemases have an inducible expression. Cephalosporinases that 
are induced by imipenem is a good example for the above. Amp C 
betalactamases are induced by Cefoxitin.36 
 However, it is not known if the actual inducer is the betalactam antibiotic itself 
or the destruction of cell wall as a result of the action of betalactam antibiotic 
on PBPs.36 
 Alterations affecting the promoter region of the gene and also in the insertion 
sequence (IS) element lead to drug resistance in an organism.36 The insertion 
sequence element causes increased transcript expression because of the signals 
it can generate and initiate transcription.37 
 If the genes that encode for Carbapenemases are encoded/ located on 
chromosomes, they spread very slowly but if they are located on plasmids, they 
spread rapidly as in case of plasmid encoded Metallobetalactamase gene in 
Klebsiella.36 
3.17 MOST COMMON TYPES OF CARBAPENEMASES 
Table 8 Most common types of Carbapenemases10 
Class Carbapenemase Enterobacteriaceae Nonfermenters 
A1 KPC +++ + 
B(Metallobetalactamases) NDM, VIM, IMP +++ +++ 
D OXA-48 +++ +/- 
 
3.17.1 CHROMOSOMAL AND PLASMID ENCODED ENZYMES AMONG 
THE DIFFERENT CLASSES: 
A. Molecular ClassA enzymes: 
Chromosomally encoded enzymes: 
SME (for Serratia marscescens), IMI (for imipenem hydrolyzing β-lactamase) 
and NMC (for Non Metalloenzyme Carbapenemase) are chromosomally encoded. 10 
Plasmid encoded Carbapenemases:  
KPC and GES are plasmid encoded classA Carbapenemases.10 
KPC (for Klebsiella pneumoniae Carbapenemase):  
Though KPC are predominant in K.pnemoniae, these betalactamases were also 
found to be the cause of drug resistance in other members of Enterobacteriaceae like 
Salmonella and E.coli. The organisms producing these Carbapenemases are resistant 
to all Monobactams and Carbapenems in addition to penicillins and Cephalosporins, 
but they are susceptible to betalactamase inhibiting drugs like Piperacillin-
Tazobactam. The genes responsible for the production of Klebsiella pneumoniae 
Carbapenemases are horizontally transferred, confering KPC enzyme with an 
extraordinary spreading capacity.10  
B. Molecular Class B enzymes: 
Chromosome borne MBLs: 
  BCI, BCII from Bacillus cereus, CphA from Aeromonas spp, L1 from 
Stenotrophomonas maltophilia, Bacteroides fragilis (CcrA) are chromosome 
mediated.10 
 
Plasmid borne MBLs: 
Metallobetalactamases that are plasmid borne have gained importance because 
of their tendency to spread all over the world. Verona integron mediated 
Metallobetalactase, Imipenem hydrolysing betalactamase, Guiana extended spectrum 
betalactamase, Seoul imipenemase and NewDelhi Metallobetalactamase are some of 
the plasmid mediated Metallobetalactamases. Of these, NDM is the most common one 
in India.10 
New Delhi Metallobetalactamase was reported for the first time in a patient in Sweden 
who was an Indian by origin and had also been hospitalised in India for treatment.10 
Klebsiella pneumoniae was the bacteria isolated from him.10 NDM-1 enzyme is now 
found to spread worldwide in a rapid manner. Outbreaks due to NDM were mostly 
linked to India and Balkan countries. NDM-1, NDM-2 to NDM-6 and NDM-7 are the 
variants of NewDelhi Metallobetalactamases. These enzymes spread rapidly between 
bacteria, because of their location on plasmids. The strains harbouring NDM show a 
broad spectrum of resistance to other betalactam antibiotics, which has left us with 
very meagre treatment options. Their prevalence in Enterobacteriaceae all over the 
world is highly suggestive of their intense ability to spread.10 Infection with 
Metalloenzyme producers have a high mortality rate exceeding sixty percent.10 
C. Class D enzymes: 
  Oxacillinases are enzymes which inactivate Oxacillin. OXA-23 and OXA-48 
are plasmid borne and OXA-50 and OXA-54 are chromosome encoded.10  
 
 
3.18 LABORATORY DETECTION OF CARBAPENEMASES: 
 CLSI suggested detecting Carbapenemases for epidemiological and academic 
purposes rather than routine testing.37 
3.18.1. SCREENING TESTS FOR CARBAPENEMASES (PHENOTYPIC 
METHODS):  
3.18.1.1 SCREEN AGARS FOR CARBAPENEMASE PRODUCERS: 
  Chromogenic media like KPC CHROM agar, Brilliance CRE and Hardy 
CHROM Carbapenemase agar are commercially available to screen for 
Carbapenemase production in gram negative bacilli. 
KPC CHROME AGAR: 
Rapid detection of CRE is very much needed, for patients who are hospitalised 
in CRE endemic areas. Culturing bacteria on MacConkey agar which is supplemented 
with Carbapenem is a cheap and easy method for detection of CRE, but takes more 
time. The sensitivity and specificity of PCR is very high but the cost and other factors 
denies us of it being used routinely.38 
Chromogenic media CHROM agar has been prepared and recently introduced 
with agents that selectively allow Carbapenem resistant isolates to grow. It has the 
capacity to inhibit all Carbapenem resistant and gram positive bacterial isolates.38 The 
suspected Carbapenemase producers have to be inoculated in the media and incubated 
overnight as for other bacterial cultures. CRE cultures take on different colours 
depending on the nature of enzymes they produce 38Growth on KPC CHROM agar 
has a high sensitivity and specificity of 100% and 98.4%, respectively for detecting 
Carbapenemase producing Enterobacteriaceae.38 
3.18.1.2 ANTIMICROBIAL SUSCEPTIBILITY TESTING – KIRBY BAUER 
METHOD: 
 Antimicrobial susceptibility testing using Carbapenem antibiotic (Imipenem or 
Meropenem) provides a presumptive evidence of Carbapenemase production.43 
  However, Carbapenemase producing Enterobacteriaceae are also resistant to 
one or more of the subclass III Cephalosporins. (Cefotaxime, Ceftazidime, 
Ceftriaxone, Cefoperazone). So susceptibility to third generation 
Cephalosporins are also screened for.37 
 According to CLSI 2016, if the zone of inhibition around Meropenem (10 µg) 
or Imipenem (10 µg) disc is less than 23mm or if the MIC of the bacterial 
strain is less than 2µg/ml, it can be taken as a presumptive Carbapenemase 
producer.37 
 Ertapenem disc or Meropenem disc is recommended by CLSI for 
Carbapenemase screening as Imipenem is less effective in Carbapenemase 
detection when compared to the other two drugs.37 
 Most of the serine Carbapenemases are sensitive to the third and fourth 
generation Cephalosporins, Monobactams and Carbapenems but not 
susceptible to betalactamase inhibitors, where as the Metalloenzymes are very 
much sensitive to drugs like Aztreonam and have a poor susceptibility to 
Cephalosporins of third and fourth generation and to Carbapenems.  
 When Extended spectrum betalactamases, Ambler class C betalactamases are 
co-produced with Carbapenemases, the test is likely to become less specific, 
which makes it imperative to screen for the other betalactamases also.37 
3.18.1.3 TEN DISC METHOD 
This procedure helps in screening of an Enterobacteriaceae isolate for all β-
lactamases (ESBLs, AmpC and Carbapenemases).45Aztreonam (30), Cefotaxime(30) , 
Ceftazidime (30), Cefotaxime + clavulante (30/10), Ceftazidime + clavulante (30/10), 
Ceftriaxone (30), Cefoxitin (30), Cefepime, Ertapenem (10) and Imipenem(10) are the 
drugs for which the sensitivity of the organism is detected, by using Kirby Bauer disc 
diffusion assay. 39 
 Detection of ESBLs: 
Ceftazidime or Cefotaxime discs with and without clavulanate are used to 
detect ESBLs. If the zone increases by 5mm or above with clavulanate 
combination, the isolate is an ESBL producer.39 
 Detection of AmpC β-lactamases: 
Amp C β-lactamases are resistant to Cefoxitin and Cefotetan. High level AmpC 
producers are even resistant to Carbapenems and Aztreonam.39 
 Detection of Carbapenemases: 
Ertapenem and Imipenem discs are used to screen for Carbapenemases. If an 
isolate is R to Ertapenem and S to Imipenem, is it a possible KPC producer.39 
This ten disc procedure is a very useful screening test for all types of β-lactamases, 
which can then be confirmed by confirmatory tests. 
 
 
 
 
3.18.1.4 MIC DETERMINATION: 
MIC can be determined by using phenotypic methods like E-test. Other 
automated methods like Vitek, Microscan walkway are also used to determine MIC. 
However both these methods can produce results which are not consistent. There can 
be a few bacterial colonies within the zone of inhibition which makes the 
compatibility of E-test questionable in detection of MIC. Hyper production of Amp C 
or over expression of CTX-M can result in elevated MICs to Carbapenems.10 
3.18.1.5 THE CARBA NP TEST: 
Carba NP test is a test that differentiates Carbapenem resistance due to 
Carbapenemase production from that due to other mechanisms.40It is based 
on bacterial lysate mediated hydrolysis of Imipenem invitro, detectable by pH 
changes using the indicator phenol red from red colour to yellow or orange colour. 
The sensitivity and specificity of this test for detection of Carbapenemase production 
in Enterobacteriaceae is 100%.40 
          Isolated colonies of the suspected bacteria are mixed with a solution of 
Imipenem and phenol red indicator solution and incubated for about two hours at a 
temperature of thirty seven degrees. If Carbapenemase producers are present the 
Carbapenemase will hydrolyse the Imipenem, resulting in lowering of the pH which 
causes a change in colour of the phenol red indicator to yellow-orange from red 
colour. The colour changes within ten minutes for bacteria producing Klebsiella 
pneumoniae Carbapenemases and some more time is needed to detect other types of 
Carbapenemases.40 
 
3.18.2 TESTS FOR DETECTION OF SPECIFIC TYPES OF 
CARBAPENEMASES: 
According to CLSI 2016, Modified Hodge test is used in phenotypic 
confirmation of all types of Carbapenemases. Combined disc test and EDTA disc 
synergy test are phenotypic tests for Metallobetalactamases. Amp C disc test is done 
to detect Ambler class C Cephalosporinases. 41 
3.18.2.1 MODIFIED HODGE TEST (MHT): 
MHT is the phenotypic test used for confirmation of production of 
Carbapenemases by gram negative bacilli according to CLSI. It is most sensitive for 
detection of KPC Carbapenemases and has varying sensitivity for other types of 
Carbapenemases.37It is not done as a routine, but done for epidemiological purposes.37 
It can also give false positive results with ESBL and Amp C producers.37It is based on 
the principle that Carbapenemase produced by the test strain is sufficient to inhibit the 
action of Carbapenem antibiotic thereby allowing the growth of ATCC E.coli 25922 
near strain that is tested, producing clover leaf zone.37 
3.18.2.2 EDTA DISK SYNERGY TEST (EDS): 
  This test is done to detect MBLs in Carbapenem resistant bacteria. It is based 
on the principle that Metallobetalactamases require metal ions (Zinc) for hydrolysis of 
Carbapenems.41 Chelators like EDTA chelates the zinc ions making it unavailable for 
hydrolysing action, thus producing an enhanced zone of inhibition.41 The test has a 
sensitivity of 95% and specificity of 92% to detect MBL producers according to the 
study by Young et al. A study by Lee et al. has proved 100% sensitivity and 
specificity. MBLs are better detected by the EDS test than with MHT.41 
3.18.2.3 COMBINED DISC TEST (CDT):  
In combined disc test, as the name suggests, two discs are used. One disc 
contains the Carbapenem antibiotic and the other disc contains the antibiotic with an 
inhibitory agent. The inhibitor that is used can be Phenyl boronic acid (PBA) or 
Ethylene diamine tetra acetic acid (EDTA) depending on the type of Carbapenemase 
that is desired to be detected. The former is used to detect Klebsiella pneumoniae 
Carbapenemases and the latter is used to detect Metallobetalactamases. These 
methods are even more accurate in identifying the type of Carbapenemase.41  
3.18.2.4 E TEST – DETECTION OF METALLOBETALACTAMASES: 
Carbapenem antibiotic like Imipenem and the antibiotic with an inhibitor 
(Ethylene diamine tetra acetic acid) can be used in the form of E-strip with the 
antibiotic at one end of the strip and the drug with inhibitor at the other end, for the 
detection of Metallobetalactamase production by bacterial strains, on a Muller Hinton 
agar plate. When the MIC is decreased by three fold or more at the EDTA end, the 
isolate is identified as a Metallobetalactamase producer. In spite of some false 
negative results, this method can be used because it has a high sensitivity and 
specificity.  
3.18.2.5 AMP C DISK TEST: 
  This test helps in the detection of AmpC producers, which contribute to 
Carbapenem resistance. The sensitivity and specificity of this test in detecting Ambler 
class C β-lactamases are 100% and 98% respectively.41 
 
 
3.18.3 CONFIRMATORY TESTS FOR CARBAPENEMASES: 
 
3.18.3.1 GENOTYPIC METHODS: 
PCR is the reliable and most satisfactory method for detecting genes coding for 
Carbapenem resistance. But it cannot be done routinely because it is costly.10 
Genotyping is mainly of epidemiological value.10 
 
3.18.3.2 DNA HYBRIDIZATION:  
DNA hybridization is being used for the detection of resistance determining 
genes or the genes that are responsible for resistance to Carbapenems. Special 
hybridization techniques can detect the presence of gene and the location of the gene 
as well, that is, whether the gene is in the chromosome or in the plasmid.10 
 
3.18.3.3 POLYMERASE CHAIN REACTION (PCR): 
This test is made the most specific by complete gene sequencing and use of 
primers that are specific for the resistant gene that is to be detected. It is also highly 
sensitive. This is the gold standard test for identifying Carbapenem resistance 
determining genes.10 Bio fire and Nanosphere are other molecular techniques to detect 
Carbapenemases.10 
 
 
 
 
3.19 ANTIBIOTICS TO TREAT CRE INFECTIONS: 
  Studies were carried out in critically ill patients with CRE infections with 
single drug treatment and combination therapy with Tigecycline, Colistin and 
Carbapenems and have concluded that mortality of critically ill patients were lower 
when treated with combination therapy than with monotherapy43.  
COLISTIN: 
Polymyxin B and Colistin are the agents which show maximum invitro activity 
against CRE.48 Higher doses, may cause nephrotoxicity and drug resistance can occur 
with monotherapy. Patients treated with antibiotics in combination with Colistin 
survived better.43 
TIGECYCLINE: 
Though many CRE show good invitro activity against Tigecycline; there is 
increasing resistance to Tigecycline with monotherapy.49Tigecycline treatment may 
be very beneficial and efficacious when we use the drug in doses higher than usual 
and when Tigecycline is used in combination with another antibiotic for serious CRE 
infections.44  
FOSFOMYCIN: 
Oral fosfomycin has been successfully used for treating UTIs as approved by FDA.44 
AMINOGLYCOSIDES: 
Aminoglycoside treatment was found to clear resistant organisms better when 
compared with either Polymyxin B or Tigecycline44. The combination of a 
Carbapenem and an Aminoglycoside had the lowest mortality rate.44 
3.19.1 COMBINATION THERAPY: 
Decreased mortality, Potential synergistic effects and reduction of emerging 
resistance are the benefits of combination therapy. However, the risk for development 
of Clostridium difficile infection is high. The risk of adverse effects like 
nephrotoxicity is also increased45. The benefits are more than the risks and hence 
combination therapy is recommended for CRE.45 
3.20 EMERGING NEWER TREATMENT OPTIONS FOR CRE INFECTIONS: 
Ceftazidime-Avibactam is a combination drug that was approved in 2015 by 
FDA for the treatment of infections of the abdomen and urinary tract that were highly 
complicated.44It has activity against all Carbapenemases except Metallo-β-
lactamases44. Patient receiving Ceftazidime-Avibactam can experience constipation, 
seizures, vomiting and hypersensitivity as adverse effects. 46 The drug is under phase 
III trial.44 
The burden of resistance to antibiotics is going on increasing day by day in gram 
negative bacteria. Organisms resistant to Carbapenems are on rapid raise, especially 
the members of Enterobacteriaceae. There are very limited drugs/ antibiotics that can 
successfully treat these infections. So correct dose of antibiotics, that too under true / 
absolute indications alone can help prevent further spread of resistance to antibiotics.44 
  
 
 
4. MATERIALS AND METHODS 
 Design of the study: Hospital based Prospective cross sectional study. 
 Study period: October 2014 to December 2015 (1 year and 3 months). 
 Setting : Department of Microbiology of tertiary care hospital. 
 Material for the study: All gram negative bacilli isolated from heterogenous 
clinical samples like urine, sputum, blood, pus, and other body fluids  received 
in our laboratory for bacterial culture and identified as members of 
Enterobacteriaceae by standard laboratory tests were included in the study. 
 Inclusion criteria:  Gram negative bacilli that are isolated from heterogenous 
clinical samples and identified as members of Enterobacteriaceae showing 
resistance and intermediate sensitivity to Carbapenems by standard laboratory 
tests. 
 Exclusion criteria: Gram negative bacilli that are isolated from heterogenous 
clinical samples and identified as non Enterobacteriaceae and 
Enterobacteriaceae sensitive to Carbapenems by standard laboratory tests. 
 Data entry: All data were entered into a proforma sheet. 
 Data analysis: Data was analysed manually by descriptive statistics. 
 Informed consent: Obtained. 
 Ethical committee approval: Enclosed. 
 
 
 
 
4.1  PATIENT HISTORY 
Age, sex, demographic details, Clinical condition, duration of illness, antibiotic 
history and other relevant history were collected from the laboratory request forms. 
4.2  COLLECTION OF CLINICAL SAMPLES: 
All the CRRI, nurses and other paramedical staffs in the sample collection area 
were instructed to collect clinical samples from patients according to the 2015 CDC 
guidelines and were also advised to instruct the patients on the standard collection 
procedures for urine and sputum. All the clinical departments were instructed to send 
patient samples before administration of antibiotics, and to transport the samples to 
the laboratory as and when they were collected, in appropriate transport media, if 
needed without delay. 
4.3 SAMPLE PROCESSING: 
 Gram staining/ direct microscopic examination of the samples were done 
appropriately for various clinical samples. 
 Urine samples were inoculated on to Nutrient and CLED agar, Sputum 
samples onto Nutrient, blood, Chocolate and MacConkey agar. Blood, Pus 
and Body fluids onto Nutrient, MacConkey and Blood agar. Stool samples 
onto MacConkey and SS agar (Salmonella Shigella agar).  
 The culture plates were incubated overnight at 37OC. 
 Next day the colony characters were observed and the organisms were 
identified as lactose fermenters and non lactose fermenters. 
 Gram staining was done on the colonies and those colonies identified as 
gram negative bacilli were further subjected to catalase, oxidase and motility 
tests initially. 
 All gram negative bacilli which were catalase positive and oxidase negative 
were characterised as Enterobacteriaceae. 
 The isolates characterised as Enterobacteriaceae were subjected to various 
biochemical tests like tests for indole production, citrate utilisation, urease 
production, nitrate reduction, Mannitol fermentation and inoculation into 
TSI agar medium for identification of Genera and species. 
 
4.4 ANTIMICROBIAL SUSCEPTIBILITY TESTING: 
Antimicrobial susceptibility testing was done by Kirby Bauer disc diffusion 
assay for the standard antibacterial drugs used in the Enterobacteriaceae panel 
according to 2016 CLSI guidelines (Ampicillin10μg, Gentamycin10μg, 
Amikacin10μg, Cefotaxime10μg, Cefoxitin30μg, Cotrimoxazole25μg, 
Ciprofloxacin5μg, Piperacillin-Tazobactam100/10μg, Aztreonam 30μg, 
Nitrofurantoin300μg (Only for urinary isolates) and Meropenem10 μg) using E.coli 
ATCC 25922 as Quality control.37 
Procedure (Kirby Bauer disc diffusion method): 
 The test organism was inoculated into peptone water and incubated such that it 
matches a turbidity of 0.5% Mc Farland standards and it was inoculated as a 
lawn over Muller Hinton agar (MHA) plate. Antibiotic discs were placed over 
the lawn – 6 discs in a 90 mm plate37 
 The plate was incubated at 37oC for 24 hrs and the diameters of zones of 
inhibition to various antibiotics were read and the organisms were categorised 
as Sensitive, Intermediate and Resistant to each antibiotic according to current 
CLSI guidelines.37 
 The bacterial strains that were intermediate or resistant to Meropenem were 
considered presumptive Carbapenemase producers and were taken for further 
testing. 
 
Table 9 Disc diffusion - CLSI guidelines for Carbapenems for 
Enterobacteriaceae 
Antibiotic S (mm) I (mm) R (mm) 
Meropenem >23 20-22 <19 
Imipenem >23 20-22 <19 
 
 
4.5 TESTS FOR CARBAPENEMASE PRODUCTION: 
The presumptive Carbapenemase producers were subjected to various tests to confirm 
Carbapenemase production, which included growth on KPC CHROME agar, 
Modified Hodge test, EDTA disc synergy test, Combined disc test and Amp C disc 
test. 
 
 
 
4.5.1 GROWTH ON KPC CHROME AGAR: 
KPC CHROM agar preparation powder was obtained from Himedia. The 
instruction manual was provided according to which the media was prepared and 
stored, preferably in a light free area at a temperature of 4°C .38  
 The suspected Carbapenemase producing Enterobacteriaceae(CRE) isolates 
were inoculated onto KPC chrome agar and incubated over night as for routine 
bacterial cultures.38 
 As per the manufacturer’s instruction, the isolates taking colours were 
identified as Carbapenemase producers.38 (For example. E.coli and Citobacter 
appeared magenta, Klebsiella and Enterobacter appeared metallic blue as 
shown in Figure 3. 
Figure 3 Growth of Gram negative bacilli on KPC CHROM agar 
 
The results were recorded and tabulated. 
 
 
 
4.5.2 MODIFIED HODGE TEST: 
 An overnight culture suspension of ATCC E.coli 25922 was prepared in 
peptone water, matched to 0.5 McFarland turbidity standards, diluted to one in 
ten and inoculated as lawn culture over a 90mm MHA plate as for disk 
diffusion.37 
 After waiting for 3-5 mins for drying, a Meropenem disc was placed at the 
centre of the plate. 
 Using a loop which can deliver 10 microlitre, the test organism was taken and 
streak inoculated from the disk edge towards all four directions. 4 isolates were 
tested in a plate with a single Meropenem disc. The plate was incubated at 
35+20C for 16-20 hrs. 
 The plates were examined the next day for enhanced growth around the test 
organism and the zone of inhibition giving a clover leaf appearance, which was 
indicative of Carbapenemase production37 as shown in Figure4.The results 
were recorded and tabulated. 
Figure 4 Modified Hodge test 
 
4.5.3 EDTA DISK SYNERGY TEST: 
 All the meropenem resistant isolates were simultaneously tested with 
ceftazidime and Meropenem to detect metallo-β-lactamase production.41  
 A culture suspension of the test isolate that had been incubated in broth 
overnight was taken, matched to 0.5 McFarland turbid standards and inoculated 
as a lawn on Muller Hinton Agar plate. A Meropenem disc with a potency of 
10 µg and a Ceftazidime disk with a potency of 30 µg (HIMEDIA) were kept 
on the agar plate over the lawn. EDTA disc was kept in the middle of the two 
discs with an edge to edge distance of 10mm from both the discs. 
 The plate was incubated overnight at 37o C and an expansion in the zone of 
inhibition between the EDTA disc and either of the other two disks as shown in 
figure 5 was interpreted as positive for MBL production41. The results were 
recorded and tabulated. 
Figure 5 EDTA disc synergy test 
 
 
4.5.4 COMBINED DISC TEST (CDT): 
 On a MHA plate, the test organism adjusted to 0.5 McFarland standards from 
an overnight culture suspension was inoculated as a lawn. 
 One disc with Meropenem and the other disc containing Meropenem with 
EDTA were placed over the lawn41. A 4-5mm increase in zone diameter in the 
Meropenem- EDTA disc compared to Meropenem disc alone was taken as 
positive for Metallobetalactamase production41 which is shown in Figure 6. 
The results were recorded and tabulated. 
Figure 6 Combined disc test 
 
 
 
4.5.5 TEST TO IDENTIFY AMP C PRODUCERS: 
4.5.5.1 AMP C DISK TEST:   
All the Meropenem resistant strains were subjected to Amp C disk test to detect 
the production of Ambler class C β-lactamase.41 
 An overnight culture suspension of ATCC E.coli 25922 was prepared in 
peptone water, matched to 0.5 McFarland turbidity standards and inoculated as 
lawn culture over a 90mm MHA plate as for routine disk diffusion procedure.37 
 A Cefoxitin disk with a potency of 30 microgram was placed over the lawn. 
 An empty disk moistened with sterile saline and inoculated with the test 
organism was placed at the vicinity of the Cefoxitin disk almost touching it. 
The culture plate was kept in the incubator for overnight incubation at 37o C.41 
 Blunting of the zone of inhibition of cefoxitin near the test strain inoculated 
disc was taken as indicative of the strain being a producer of Ambler class C 
betalactamase, as shown in Fig7. 41 
 The results were recorded and tabulated. 
Figure 7 Amp C disc test 
 
4.6 TESTING THE CARBAPENEM RESISTANT ISOLATES FOR 
SUSCEPTIBILITY TO TIGECYCLINE AND COLISTIN: 
Susceptibility of the Carbapenem resistant isolates to tigecycline56 and 
colistin57 was done by disc diffusion method according to EUCAST and guidelines of 
the study by Irene et al. 
Procedure (Kirby Bauer disc diffusion method): 
 The test organism was inoculated into peptone water and incubated such that it 
matches 0.5% Mc Farland turbidity and it was inoculated as lawn culture over 
Muller Hinton agar plate. 
 Tigecycline 15µg and colistin 5 µg antibiotic discs were placed over the lawn47 
 The plate was incubated at 37oC for 24 hrs and the next day the diameters of 
zones of inhibition were read and the organisms were categorised as Sensitive, 
Intermediate and Resistant accordingly.47,48 
 
Table 10 Disc diffusion – EUCAST and Irene et al guidelines for 
Tigecycline and colistin respectively for Enterobacteriaceae  
Antibiotic S I R 
Tigecycline47 >18 15-18 <14 
Colistin48 >14 12-13 <11 
 
 
4.7 GENOTYPING: 
25 CRE isolates with odd numbers, which included 16 Klebsiella spp., 7 E.coli and 2 
Proteus spp., were randomly chosen and were subjected to Genotyping to identify the 
genes blaNDM-1 and blaOXA51 by Multiplex PCR. 
 Bacterial DNA was purified and DNA was extracted from all the strains, mixed 
with specific primers and placed into the PCR machine. 
 Multiplex PCR was carried out in order to detect blaNDM-1 and blaOXA-51genes. 
 The steps of PCR are initial denaturation at 95°C for 5 mins, followed by 35 
cycles of denaturation at 94°C for 30 sec, which is inturn followed by 
annealing at 58°C for 30 sec and extension at 72°C for 30 sec, and finally an 
extension at 72°C for 5 min.  
 The products that were amplified were subjected to electrophoresis at 50 V in 
2% agarose gel stained with ethidium bromide and the bands were visualized 
under Ultraviolet light. 
The resistant genes were thus identified. 
 
 
 
 
 
 
 
5. RESULTS 
The study, “PREVALENCE, PHENOTYPING AND MOLECULAR 
DETECTION OF blaNDM-1 and blaOXA-51 GENES IN 
CARBAPENEMASE PRODUCING STRAINS AMONG THE 
CARBAPENEM RESISTANT ENTEROBACTERIACEAE” was carried out 
in the department of Microbiology, Chennai Medical college Hospital and 
research centre, Trichy and the results have been discussed with reference to 
parameters like age, gender, inpatient/outpatient details and co-morbid 
conditions. 
5.1 SAMPLES RECEIVED IN OUR LABORATORY DURING THE PERIOD 
OF STUDY: 
The distribution details for all the 6651 clinical samples received in our 
laboratory during the fifteen months (October 2014 to December 2015) study period is 
depicted in Figure 8, given below.  
Figure 8 Distribution details of samples received during the study period (Oct 
2014 to Dec 2015) 
 
Figures in parenthesis indicate the number of each clinical sample received. 
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5.2 BACTERIAL ISOLATES FROM HETEROGENOUS CLINICAL 
SAMPLES: 
The total number of bacteria that were isolated during the study period was 
4423(66.5%) out of 6651 samples that were processed. The details of the number of 
Gram positive cocci, Gram negative bacilli including Enterobacteriaceae and Non-
fermenters, contaminants and skin commensals isolated during the period of our study 
are provided in Table 11. 
Table 11 Total and Sample-wise isolation of bacteria during the study period 
Nature of 
bacteria 
Pus Sputum Urine Blood Body 
fluids 
Total %* 
GPC* 240 15 11 72 9 347 5.3 
GNB* 799 585 542 60 52 2038 30.6 
NG/Contaminant/
Commensal 
865 583 2100 429 289 4266 64.1 
Total 1904 
(28.63) 
1183 
(17.87) 
2653 
(39.89) 
561 
(8.4) 
350 
(5.21) 
6651 
(100) 
100 
 
*NG- No growth; GPC-Gram positive cocci; GNB-Gram negative bacilli; Figures in 
parenthesis indicate percentage. 
Out of 4423 bacteria that were isolated, 2038 (30.6%) were Gram negative 
bacilli, which included 1421 (69.72%) Enterobacteriaceae and 617 (30.28%) 
nonfermenters. The distribution details of the same have been furnished in Table12. 
 
Table 12 Distribution details of all Gram negative bacilli isolated during the 
study period 
Nature of 
bacteria 
Pus 
(39.2%) 
Sputum 
(26.79) 
Urine 
(24.76) 
Blood 
(4.34) 
Body fluids 
(2.55) 
Total (%) 
Enterobacteriaceae 589 285 482 33 32 1421 69.72 
Non-fermenters 210 300 60 27 20 617 30.28 
Total 799 585 542 60 52 2038 100 
 
5.3 SAMPLEWISE ISOLATION OF DIFFERENT MEMBERS OF 
ENTEROBACTERIACEAE: 
Sample wise isolation of Enterobacteriaceae has been depicted in Table 13.  
Table 13 Sample-wise isolation of different members of Enterobacteriaceae 
Enterobacteriaceae 
isolated 
Pus 
 
Sputum Urine Blood Body  
fluids 
Total %* 
E.coli 213 (36.2) 48(16.8) 354(73.4) 9(27.3) 10(31.2) 634 44.6 
Klebsiella spp., 243 (41.2) 191(67.1) 84(17.4) 18(54.5) 21(65.6) 557 39.2 
Proteus spp., 93 (15.8) 28(9.8) 20(4.2) - - 141 9.9 
Citrobacter spp., 18(3.05) 18(6.3) 12(2.5) - 1(3.2) 49 3.4 
Serratia spp., 15(2.6) - - - - 15 1.1 
Providencia spp., 7(1.2) - 12(2.5) - - 19 1.4 
Salmonella - - - 6(18.2) - 6 0.4 
Total 589 (41.4) 285 
(20.1) 
482 (33.9) 33 (2.4) 32 (2.2) 1421 100 
 
*- Figures in parenthesis indicate percentage. 
 
5.4 DISTRIBUTION OF CARBAPENEM RESISTANT 
ENTEROBACTERIACEAE (CRE): 
Out of 1421 Enterobacteria, Carbapenem resistance was observed in 
56(3.94%) isolates that consisted of 25 Klebsiella spp., 21 E.coli, 8 Proteus spp., and 
2 Citrobacter spp., on disc diffusion assay using Meropenem according to CLSI 
guidelines 2016.                
Figure 9 Total number of bacterial isolates including CRE 
 
5.5 GENDERWISE DISTRIBUTION OF CRE: 
Out of 56 isolates, 35(62.5%) were from males and 21(37.5%) were from 
females. The distribution of CRE in relation to gender is shown in Figure 10.  
Figure 10 Gender-wise distribution of CRE 
 
       Figures in parenthesis indicate the number of isolates from each gender. 
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5.6 AGE AND GENDERWISE DISTRIBUTION OF CRE: 
The CRE isolates were more from males and it was significant. Similarly the 
CRE were more from the 51 and above age group. The youngest patient from whom 
the CRE was isolated belongs to the 11-20 age group and the oldest to the above 60 
age group. The distribution of the CRE isolates in relation to age and gender is 
depicted in Table14. 
 
Table 14 Distribution of CRE in relation to age and gender 
Age group 
(years) 
Gender Total no. of 
isolates (%)* Male Female 
1-10 0 0 0 
11-20 1 0 1(1.78) 
21-30 1 1 2(3.57) 
31-40 3 5 8(14.28) 
41-50 1 4 5(8.92) 
51-60 12 7 19(33.92) 
>60 17 4 21(37.5) 
TOTAL 35(62.5%) 21(37.5%) 56 
 
*-Figures in parenthesis indicate percentage. 
The CRE were observed predominantly in the above 60 age group. 
 
5.7 DISTRIBUTION OF CARBAPENEM RESISTANCE IN DIFFERENT 
MEMBERS OF ENTEROBACTERIACEAE: 
Table 15 depicts the distribution of Carbapenem resistance in various members 
of Enterobacteriaceae. 
Table 15 Distribution of Carbapenem resistance in different members of 
Enterobacteriaceae 
Enterobacteriaceae 
member 
Total no 
Meropenem 
resistance (%) 
E.coli 634 21(3.31) 
Klebsiella spp., 557 25(4.49) 
Proteus spp., 141 8(5.67) 
Citrobacter spp., 49 2(4.08) 
Total 1381 56 
 
5.8 DISTRIBUTION OF VARIOUS MEMBERS OF CARBAPENEM 
RESISTANT ENTEROBACTERIACEAE: 
Out of 56 CRE isolates, 25(44.64%) were Klebsiella spp., which included 24 
Klebsiella pneumoniae and 1 Klebsiella oxytoca, 21(37.5%) were E.coli, 8(14.29%)  
were Proteus spp., which included 4 Proteus mirabilis and 4 Proteus vulgaris and 
2(3.6%) were Citrobacter spp., comprising 1 Citrobacter koseri and 1 Citrobacter 
freundii. The details have been furnished in Figure11. 
 
 
Figure 11 Distribution of CRE in relation to organisms 
 
5.9 DISTRIBUTION OF CARBAPENEM RESISTANCE IN 
ENTEROBACTERIACEAE IN VARIOUS CLINICAL SAMPLES: 
The distribution of Carbapenem resistance in Enterobacteriaceae with regard to 
clinical samples is provided in Table16. 
Table 16 Distribution of CRE in various clinical samples 
Nature of Sample Total no of 
Enterobacteriaceae 
Carbapenem 
resistance n (%) 
Pus 589 40(6.79) 
Sputum 285 11(3.86) 
Urine 482 5(1.04) 
Blood 33 - 
Body fluids 32 - 
Total 1421 56 
 
5.10 DISTRIBUTION OF DIFFERENT MEMBERS OF CARBAPENEM 
RESISTANT ENTEROBACTERIACEAE IN RELATION TO VARIOUS 
CLINICAL SAMPLES: 
The distribution of CRE in relation to organisms and clinical samples is 
described in Figure12. 
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Figure 12 Distribution of various members of CRE in relation to clinical samples 
 
              Figures in parenthesis indicate the number of each bacterial isolate. 
CRE were more in pus samples probably due to indiscriminate antibiotic use. No CRE 
was isolated from blood and body fluids. 
5.11 DISTRIBUTION OF CRE IN RELATION TO IN-PATIENTS AND OUT-
PATIENTS: 
Figure13 represents the percentage of in and out-patients with CRE infections. 
Figure 13 Distribution of CRE in relation to In-patients and out-patients 
 
        Figures in parenthesis indicate the number of in-patients and out-patients. 
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5.12 DISTRIBUTION OF CRE IN RELATION TO WARDS: 
As expected the isolates were more from surgical wards (40/56) making 
71.43% as against 16/56 (28.57%) from medical wards and the distribution is 
statistically significant as shown in Table17 
 
Table 17 Distribution of CRE in relation to wards (56 No.) 
 
S No Ward E.coli Klebsiella 
spp., 
Citrobacter 
spp., 
Proteus 
spp., 
Total % 
1 Surgery* 7 13 2 4 26 46.43 
2 Orthopaedics* 2 2 - - 4 7.14 
3 Burns* 1 - - 1 2 3.57 
4 OG* 3 2 - - 5 8.93 
5 Casualty* 1 1 - 1 3 5.36 
6 Chest 
medicine** 1 3 - 1 5 
8.93 
7 ICU** 1 1 - 1 3 5.36 
8 Medicine** 4 2 - - 6 10.71 
9 Dermatology** 1 1 - - 2 3.57 
 Total 21 25 2 8 56 100 
 
* - Surgical wards; **- Medical wards 
 
 
 
 
 
 5.13 DISTRIBUTION OF CO-MORBID CONDITIONS AMONG THE CASES 
WITH CRE INFECTIONS: 
A total of 35 out of 56 (69.64%) patients who harboured CRE isolates had one 
or the other co-morbid condition and the details are furnished in Table18. 
 
Table 18 Co-morbid conditions associated with CRE infections 
S No Co-morbid condition Number 
(%)* 
1.  Type 2 Diabetes Mellitus 24 (42.86) 
2.  Pulmonary Tuberculosis(PT)/ Post PT 3 (5.36) 
3.  Systemic Hypertension 3 (5.36) 
4.  Urinary Catheterisation 8 (14.27) 
5.  Chronic Kidney Disease 1 (1.7) 
6.  No co-morbid condition 17 (30.36) 
Total  56 
 
*- Figures in parenthesis indicate percentage. 
 
Co-morbid conditions predispose to delayed response to treatment of the 
underlying infection, requiring prolonged antibiotic therapy which results in drug 
resistance. 
 
 5.14 ANTIBIOTIC SENSITIVITY PATTERN OF VARIOUS CRE: 
 
5.14.1 SENSITIVITY OF THE CRE ISOLATES TO ENTEROBACTERIACEAE 
PANEL OF DRUGS ACCORDING TO 2016 CLSI GUIDELINES: 
Six out of 56 CRE isolates (16.1%) were sensitive to Gentamycin, which included 2 
E.coli and 4 Klebsiella spp., 15/56 CRE isolates (26.78%) were sensitive to Amikacin, 
which included 6 E.coli, 6 Klebsiella spp., 2 Proteus spp., and 1 Citrobacter spp., 
30/56 CRE isolates (53.57%) were sensitive to Cefoxitin, which included 15 E.coli, 4 
Proteus spp,. and 11 Klebsiella spp.,  All the CRE isolates were found to be resistant 
to Ampicillin, Ciprofloxacin, Cotrimoxazole, Ceftriaxone, Cefotaxime, Cefoperazone 
– Sulbactam, Aztreonam, Imipenem and Meropenem according to 2016 CLSI 
guidelines. All the 56 (100%) isolates were found to be susceptible to Colistin and 
Tigecycline. 
 
5.15 RESULTS OF THE PHENOTYPIC TESTS FOR DETECTION OF 
CARBAPENEMASES IN CRE: 
5.15.1 GROWTH ON KPC CHROME AGAR: 
On screening all the 56 isolates with KPC chrome agar, 52 (92.86%) grew on KPC 
chrome agar indicating Carbapenemase production, which has been depicted in 
Figure14. 
Figure 14 Distribution of Growth of CRE on KPC chrome agar
 
Figures in parenthesis indicate the number of positive and negative isolates. 
5.15.1.1 Growth of various members of CRE on KPC chrome agar: 
Out of the 52 isolates that were positive for growth on KPC chrome agar, 
23(44.23%) were Klebsiella spp., followed by 19(36.53%) E.coli, 8(15.38%) Proteus 
spp., and 2 (3.85%) Citrobacter spp.,  
The distribution of the organisms is given in Figure15. 
Figure 15 Growth of CRE members on KPC chrome agar 
 
*- Figures in parenthesis indicate the number of each CRE isolate positive for growth 
on KPC chrome agar. 
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5.15.2. MODIFIED HODGE TEST (MHT): 
Out of the 56 isolates that were tested by MHT, 38 (67.86%) were MHT 
positive and the remaining 18(32.14%) were negative which has been depicted in 
figure16. 
Figure 16 MHT results of the CRE isolates 
 
Figures in parenthesis indicate the number of MHT positive and negative isolates 
 5.15.2.1 Distribution of MHT positivity in relation to various members of CRE: 
MHT positives consisted of 17 (45%) Klebsiella spp., 15 (39%) E.coli, and 6 
(16%) Proteus spp., which is depicted in the figure17. 
Figure 17 Distribution of MHT positivity in relation to members of CRE 
 
Figures in parenthesis indicate the number of each CRE isolate positive for MHT. 
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5.15.3 RESULTS OF EDTA DISC SYNERGY (EDS) TEST: 
EDS test was performed on all the 56 isolates, out of which 44(78.57%) were 
found to be positive and 12(21.43%) were negative, which is depicted in Figure18. 
Figure 18 EDS test results of CRE isolates 
 
Figures in parenthesis indicate positive and negative number for EDS test. 
5.15.3.1 EDS test results in relation to various members of CRE: 
Among the 44 isolates positive by EDS test, 15(34.09%) were Klebsiella spp., 
19(47.5%) were E.coli, 8(20%) were Proteus and 2(5%) were Citrobacter spp., and 
the same is depicted in Figure19. 
Figure 19 EDS test results in relation to various members of CRE 
 
*- Figures in parenthesis indicate the number of each CRE isolate positive for EDS 
test. 
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5.15.4 RESULTS OF COMBINED DISC TEST (CDT): 
Out of the 56 isolates tested, 44(78.57%) were positive and 12(21.43%) were 
negative for CDT (Combined disc test), which is shown in Figure 20. 
Figure 20 Combined disc test (CDT) results of CRE isolates 
 
Figures in parenthesis indicate the number isolates positive and negative for CDT. 
5.15.4.1 CDT results in relation to various members of CRE: 
Among the 44 isolates that tested CDT positive 15(34.09%) were Klebsiella 
spp., 19(47.5%) were E.coli, 8(20%) were Proteus spp., and 2(5%) were Citrobacter 
spp., which was similar to that of EDS test as shown in figure21. 
Figure 21 CDT positivity in relation to various members of CRE 
 
Figures in parenthesis indicate the number of each CRE isolate positive for CDT. 
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5.15.5 AMP C DISC TEST: 
Out of 56 Carbapenem resistant isolates tested, 26(46.43%) were positive and 
30 isolates (53.57%) were negative. The details are furnished in Figure 22. 
Figure 22 Amp C disc test results of CRE isolates 
 
Figures in parenthesis indicate the positive and negative numbers. 
5.15.5.1 Results of Amp C disc test in relation to various members of CRE: 
The Amp C disc test was positive in 14(53.85%) Klebsiella spp., 6(23.07) 
E.coli, 4(15.38%) Proteus spp., and 2(3.57%) Citrobacter spp., The details are given 
in Figure 23. 
Figure 23 Amp C disc test positivity in relation to various members of CRE
 
Figures in parenthesis indicate the number of each CRE isolate positive for AmpC 
disc test. 
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5.16 CRE AND PHENOTYPIC TESTS – CUMULATIVE RESULTS: 
The cumulative results of the phenotypic tests performed with the CRE isolates 
have been depicted in Figure 24. 
 
Figure 24 Positivity of CRE isolates for various phenotypic tests (Blue-Klebsiella 
spp., Green - E.coli, Brown-Proteus spp., Pink-Citrobacter spp.,) 
 
*-White boxes indicate negative test results. Coloured boxes indicate positive test 
results. 
 Out of 25 Carbapenem resistant Klebsiella isolates, 1 was positive for all the 
five phenotypic tests, 10 for 4 tests except Amp C disc test, 4 for 4 tests except 
MHT, 5 for KPC and MHT and Amp C alone, 2 for AmpC test alone, 1 for 
MHT and Amp C test alone, 1 for KPC alone, 1 KPC and Amp C alone. 
 One E.coli isolate was positive for all the five phenotypic tests. 12 for all the 
tests except AmpC disc test, 4 for all tests except MHT, 1 for 3 tests except 
EDS and CDT, 1 for 3 tests except MHT and AmpC disc test and 1 isolate was 
negative for all the five tests.  
 Three Carbapenem resistant Proteus isolates were positive for all the five 
phenotypic tests, 3 for four tests except Amp C disc test and 1 for all tests 
except MHT and 1 negative only for MHT and Amp C tests. 
 Both the Citrobacter isolates were positive for all phenotypic tests except 
MHT.  
 
5.17 RESULTS OF GENOTYPING - CRE: 
     Of the 56 CRE isolates, genotyping was done only for 25 isolates with odd 
numbers due to technical limitations. Out of the 25, 21 were positive for atleast one of 
the target genes. Figure 25 and Figure 26 shows the results of genotyping. Table 19 
shows the results of genotyping of CRE isolates for blaNDM-1 and blaOXA-51 genes. 
The table is also furnished with the details that can help us compare the results of 
phenotypic and genotypic methods. 
 
 
 
 
 
 
 
 
 Figure 25 Results of genotyping – molecular detection of blaNDM-1 gene 
 
*-P is Positive; N is Negative; L is Ladder 
Figure 26 Results of genotyping – molecular detection of blaOXA-51 gene 
 
 
*-P is Positive; N is Negative; L is Ladder 
5.18 COMPARISON BETWEEN PHENOTYPIC AND GENOTYPIC TEST 
RESULTS OF CRE: 
      Twenty one out of 25 (84%) tested CRE isolates were found positive for atleast 
one of the target genes. Out of the 25 isolates that were tested for blaNDM-1 and 
blaOXA-51, 20(80%) were found positive for blaNDM-1 gene and 8(40%) were positive 
for blaOXA-51 gene. 7(28%) isolates were positive for both the genes. 13(52%) were 
found positive for blaNDM-1 alone and was blaOXA-51 negative. 1(4%) was found 
positive for blaOXA-51 alone and was blaNDM-1 negative. Out of the 20 blaNDM-1 
positive isolates, 11 (55%) were Klebsiella spp., 7(35%) were E.coli and 2(10%) were 
Proteus spp., 11 out of 16(68.75%) Klebsiella spp., 7 out of 7 E.coli (100%) and 2 out 
of 2 Proteus spp., isolates were found positive for blaNDM-1. The details have been 
furnished in table 19. 
 
 
 
 
 
 
 
 
 
 
 
Table 19 Comparative results – Phenotyping and genotyping 
S.NO CRE ISOLATE KPC MHT EDS 
TEST 
CDT AMP C 
TEST 
blaNDM-1 blaOXA-51 
1 Klebsiella spp. + + - - + N P 
2 Klebsiella spp. + + + + - P P 
3 Klebsiella spp. + + + + - P P 
4 Klebsiella spp. + + + + - P N 
5 Klebsiella spp. + + + + - P P 
6 Klebsiella spp. + - - - - N N 
7 Klebsiella spp. + - - - - N N 
8 Klebsiella spp. + - + + + P N 
9 Klebsiella spp. + - + + + P N 
10 Klebsiella spp. + - + + - P N 
11 Klebsiella spp. + - + + + P N 
12 Klebsiella spp. - - + + + P N 
13 Klebsiella spp. + - + + + P P 
14 E.coli + + + + - P N 
15 E.coli + + + + - P N 
16 E.coli + + + + - P P 
17 E.coli + + + + - P N 
18 E.coli + + + + - P N 
19 E.coli + + + + - P N 
20 Proteus spp + + + + - P N 
21 Proteus spp + + + + + P P 
22 Proteus spp + + + + - P P 
23 E.coli - - - - + N N 
24 Klebsiella spp. + + - - + N N 
25 Klebsiella spp. - + + + - P N 
 
 
6. DISCUSSION 
Drug resistant Enterobacteriaceae isolates have been found to cause many 
hospital and community acquired infections, Carbapenemase producing 
Enterobacteriaceae (CRE) being the most important and highly resistant amongst 
them all, causing high morbidity and mortality, making it imperative to conduct this 
study. 
In this study, Carbapenemase producing Enterobacteriaceae were identified 
from heterogeneous clinical samples, their prevalence in various samples was studied, 
their distribution with respect to parameters like age, gender and clinical samples were 
analysed and their sensitivity patterns were studied. In addition, the different types of 
Carbapenemases were identified according to the phenotypic and genotypic methods. 
6.1 SAMPLES RECEIVED IN OUR LABORATORY: 
Urine (39.89%) was the most frequent sample received in our study, followed 
by pus (28.63%), sputum (17.87%), blood (8.4%) and body fluids (5.21%). The 
reason for this could be Urinary tract infection (UTI) being the most common hospital 
acquired infection accounting for more than forty percent.49 
6.2 TOTAL NUMBER OF GRAM NEGATIVE BACILLI AND 
ENTEROBACTERIACEAE ISOLATED DURING THE PERIOD OF STUDY: 
The number of culture positives in total from all clinical samples during the 
study period was 4423(66.5%) which included 347(5.3%) gram positive cocci and 
2038 (30.6%) gram negative bacilli. The remaining 4266 (64.1%) included 
commensals, contaminats and samples where no growth were observed. This is in 
concordance with the study by Sankarankutty et al where Gram negative isolates 
constituted 70.86% of culture positives.50 
Out of 2038 gram negative bacilli, 1421(69.72%) were Enterobacteriaceae 
isolates and the remaining 617(30.27%) were non-fermenters. This finding is in 
concordance with the study by Lockhart et al where Enterobacteriaceae constituted 
60% of the gram negative bacilli. It is also in agreement with the study by 
Sankarankutty et al where Enterobacteriaceae constituted 84.8% of the Gram 
negative isolates50. 
In our laboratory, the commonest Enterobacteriaceae isolated is E.coli 
(44.6%). The second most common is Klebsiella spp., (39.2%), followed by Proteus 
spp., (9.9%), Citrobacter spp., (3.4%), Providencia spp., (1.4%), Serratia spp., (1.1%) 
and Salmonella spp., (0.4%). This finding is concordant with the results a study by 
Sankarankutty et al where E.coli (55.3%) was the predominant member of 
Enterobacteriaceae that was isolated, followed by Klebsiella spp., (17.64%), Proteus 
spp., (4.7%) Citrobacter spp.,(3.92%), Enterobacter spp., (2.74%) and Providencia 
spp., (1.96%) in that order50. 
Pus (41.4%) is the sample from which most of the Enterobacteriaceae isolates 
were obtained in this study, followed by urine (33.9%), sputum (20.1%), blood (2.4%) 
and body fluids (2.2%). In a study by Sankarankutty et al, most of the 
Enterobacteriaceae were the isolates from Urine (72.60%), pus (18.26%), sputum 
(6.96%) and blood (1.3%) in that order50. Pus was the predominant sample harbouring 
Enterobacteriaceae in this study. This might be due to the reception of more number 
of pus samples from surgical ward patients and post operative patients in our setting. 
6.3 SAMPLE WISE PREVALENCE OF ENTEROBACTERIACEAE 
ISOLATES: 
In pus samples, Klebsiella spp., (41.2%) was the predominant isolate, followed 
by E.coli (36.2%), Proteus spp.,(15.8%), Citrobacter spp.,(3.05%), Serratia(2.6%) 
and Providencia(1.2%). This is in concordance with the study by Sunilkumar et al 
where Klebsiella spp.,(50%) was the predominant isolate from pus samples51. In a 
study by Soumya et al E.coli(50%) was the predominant isolate in pus samples, 
followed by Proteus spp.,(23.8%), Klebsiella spp.,(19.05%), Citrobacter spp.,(4.76%) 
and Providencia(2.4%)50. This discordance may be due to a relatively higher 
prevalence of Klebsiella spp., in our hospital, especially in post operative patients 
from whom most of the pus samples were received. 
In sputum samples, Klebsiella spp., (67.1%) was the predominant isolate, 
followed by E.coli (16.8%), Proteus spp., (9.8%) and Citrobacter spp., (6.3%), which 
is in correlation with the study by Vesna where Klebsiella spp., was the predominant 
isolate from sputum samples in patients with infectious diseases of the respiratory 
tract52. 
In urine samples, E.coli (73.4%) was the predominant isolate, followed by 
Klebsiella spp.,(17.4%), Proteus spp.,(4.2%), Citrobacter spp.,(2.5%) and 
Providencia(2.5%). This is in concordance with many studies, an article by Sobia et al 
being one of them where E.coli was the predominant pathogen isolated from urine 
samples and is the cause for 85% of urinary tract infections53. 
In blood, Klebsiella spp., (54.5%) was the predominant isolate, followed by 
E.coli(27.3%) and Salmonella(18.2%)in our study, which is in concordance with the 
results of a study by Jose et al, where Klebsiella spp.,(26.3%) was the predominant 
isolate from blood in patients with blood stream infections, followed by E.coli (21 
%).54 
In body fluids, Klebsiella spp., (65.6%) was the most commonly isolated, 
followed by E.coli(31.2%) and Citrobacter spp.,(3.2%). Most of the isolates were 
from Broncho alveolar lavage (BAL) fluid (50%) and Klebsiella spp., (12/16 
constituting 75% of Enterobaceriaceae isolates from BAL fluid) was the predominant 
Enterobacteriaceae isolate from BAL fluid in our study, followed by E.coli (4/16 
constituting 25%) 
E.coli was the predominant isolate from peritoneal fluid in our study (3 out of 
6, 50%), followed by Klebsiella spp., (2 out of 6) and Citrobacter spp., (1 out of 6). 
According to an article by Thiago et al published in 2011, E.coli (70%) was the 
commonest microbe to be isolated from cases of bacterial peritonitis, followed by 
Klebsiella spp., which is in concordance with our study55.  
Klebsiella spp.,was the only member of Enterobacteriaceae isolated from 
synovial fluid. The most frequently isolated member of Enterobacteriaceae from 
synovial fluid was E.coli according to a study by Mark et al56.  
Both Klebsiella spp., and E.coli were isolated from pleural fluids – 1 each. This 
is in concordance with the results of a study by Moon et al where Klebsiella spp., was 
the predominant isolate from pleural fluids.57 
 
 
 
6.4 PREVALENCE OF CRE: 
Out of all the 1421 Enterobacteriaceae isolates, 56(3.94%) were found to be 
resistant to Meropenem by disc diffusion assay according to 2016 CLSI guidelines. So 
in our setting, the prevalence of Carbapenem resistant Enterobacteriaceae (CRE) 
according to our study was 3.94%. Yanling et al. in an Asian study have detected that 
the prevalence of CRE was 0.6% in 2001 and 1.3% in 201258. Comparison of our 
study results with that of Yangling et al shows that Carbapenem resistance has been 
gradually rising since last decade. The overall incidence rate of CRE was 2.93% 
according to a study by Alice et al in 201559. Datta P et al found the prevalence of 
CRE in their study to be 7.87%.60 The prevalence of CRE according to the study by 
Nair P K et al was 12.26%61.The results of all these studies clearly indicate an 
increasing incidence of Carbapenem resistance all over, warranting immediate action 
to stop emergence of further resistance. 
6.5 AGEWISE DISTRIBUTION OF CRE: 
In our study, patients above 60 yrs of age are found to be predominantly 
affected, constituting 37.5%, which is similar to the results of Meenakumari et al 
where the majority of patients infected by CRE were above 60 years of age. This 
finding also correlates with a study by Brennan et al where most of the patients 
infected with CRE were above 60 years of age62.The high susceptibility of this age 
group may be due to the high prevalence of co-morbid conditions like Diabetes, 
Chronic Kidney disease (CKD), cancer and other immunocompromised conditions in 
this group63. 
 
6.6 GENDERWISE DISTRIBUTION OF CRE: 
In this study there was an increased  prevalence of CRE in males (62.5%) 
compared to females(37.5%).This finding is concordant with the findings of Gabriela 
et al., where the prevalence of Carbapenemase producing Enterobacteriaceae was 
higher in males (72.5%) compared to females (27.5%). This finding is also in 
concordance with a study by Kalidas et al., where the prevalence in males was 55% 
and it was 45% in females. 51% of the CRE infected patients were males according to 
a study by Brenner et al62. This higher male preponderance may be due to the 
associated non modifiable risk factors in males like their male gender itself, age, 
increased incidence of diabetes, Hypertension and CKD63. Though females are 
susceptible to these factors, they are protected to a greater extent by their hormonal 
factors until they attain menopause at an average age of 51 years, after which both the 
genders are equally susceptible to the risk factors64. 
 40% of Urinary tract infections in our study group have occurred in 
postmenopausal women. Increased incidence of Urinary tract infection in females of 
postmenopausal age group can largely be attributed to the alkaline pH of the 
genitourinary epithelium due to depletion of lactobacillus, which had protected them 
in their premenopausal age65. 
6.7 PREVALENCE OF CARBAPENEM RESISTANCE IN EACH MEMBER 
OF ENTEROBACTERIACEAE: 
Twenty one out of 634(3.31%) E.coli isolates, 25 of 557(4.49%)  Klebsiella 
spp., 8(5.67%) of 141 Proteus spp., and 2(4.08%)  out of 49 Citrobacter spp., were 
found to be resistant to Meropenem and so the prevalence of Carbapenem resistant 
Proteus spp., E.coli, Klebsiella spp., and Citrobacter spp., according to this study are 
5.67%, 3.31%, 4.49%, and 4.08% respectively. The prevalence of Carbapenem 
resistant E.coli, Klebsiella spp., and Enterobacter spp., were 7.3%, 4.1% and 0.9% 
respectively according to a study by Nair et al which correlates with our study 
results61. 
6.8 SAMPLE WISE DISTRIBUTION OF CRE: 
Forty out of 589 (6.79%) Enterobacteriaceae from pus samples, 11 out of 
285(3.86%) from sputum samples and 5 out of 482(1.04%) from urine samples are the 
prevalence of CRE in each sample according to our study. In a study by Nair et al, 
46% of CRE were from urine samples, 16% from pus and 7% from sputum samples61. 
The higher prevalence of CRE from pus samples in our study shows that the surgical 
and post-operative wards of our healthcare setting are lagging behind in infection 
control practices, as most of the pus isolates in our study were received from surgical 
and post-operative wards. 
Out of the 56 CRE isolated in our study, most of them were from pus samples 
which included drainage tube (71.42%), followed by sputum (19.64%) and urine 
(8.73%) samples. There were no CRE isolates from blood and body fluids. This 
finding is in concordance with a study by Saveetha et al where most (52%) of the 
isolates were from pus samples66. In a study by Pratita et al, pus (24%) was the second 
common sample from which CRE were isolated next only to urine67.  
 
 
 
6.9 ORGANISM WISE DISTRIBUTION OF CRE: 
Out of the 56 CRE isolated in this study, 25(44.64%) were Klebsiella spp., 
spp., 21(37.5%) were E.coli, 8(14.29%) were Proteus spp., and 2(3.6%) were 
Citrobacter spp.,  
In this study, Klebsiella spp., was the predominant Carbapenemase producer, 
followed by E.coli, Proteus spp., and Citrobacter spp., which are concordant with a 
study by Rosmari et al where the most common member of Enterobacteriaceae 
producing Carbapenemase was Klebsiella spp., and the second most common  was 
E.coli, followed by Proteus spp., and Citrobacter spp., in that order68. It is also similar 
to the finding of a study conducted by Chuang et al., where Klebsiella spp., (58.1%) 
was the predominant isolate followed by Enterobacter (26.5%) and E.coli (9.4%). 
6.10 CRE PREVALENT IN INDIVIDUAL SAMPLES: 
In pus samples Klebsiella spp., (50%) was the predominant isolate, followed by 
E.coli (32%), Proteus spp., (13%) and Citrobacter spp., (5%) This finding is in 
concordance with a study by Vijeta et al where Klebsiella spp., (28%) was the CRE 
that was predominant in pus samples, followed by Proteus spp., (5%), Ecoli (3%) and 
Citrobacter spp., (2%). In a study by Nair P K et al, Klebsiella spp., was the 
predominant CRE isolated from pus samples61, which is also in concordance with our 
study. 
E.coli was the predominant CRE in sputum samples according to this study 
(54.64%), which was followed by Klebsiella spp., (27.36%) and Proteus spp., (18%). 
In a study by P K Nair et al, Klebsiella spp.,was the predominant isolate from sputum 
samples61. E.coli was isolated from sputum in a study by Yang et al.  
In urine samples E.coli and Klebsiella spp., (40% each) were equally 
predominant followed by Proteus spp., (20%) in this study. According to the study by 
Manikandan et al., E.coli was the predominant CRE isolated from urine samples.70 
E.coli  (67.6%), was found to be the predominant CRE causing urinary tract infection 
followed by Klebsiella spp.,(8.8%) and Proteus spp.,(5.2%) in a study by Enrico et 
al71. Also in a study conducted by Vasoo et al., Carbapenem resistant E.coli was the 
predominant isolate (72%) from urine samples followed by Klebsiella spp., (15%) and 
Proteus spp., (7%).The results of these studies are concordant with the results of our 
study. 
The prevalence of Urinary tract infection was found to be more in females (3/5 
– 60%) compared to males (2/5 – 40%) in our study. This is also in concordance with 
the study by Enrico et al where female to male urinary tract infection ratio was found 
to be 3.871. According to a study conducted by Setegn et al., CRE causing Urinary 
tract infections were more common in females than in males72. The higher incidence 
of UTI in females may be attributed to short urethra in females, which favours easy 
spread of infection73. 
Three out of 5(60%) urinary CRE isolates were from patients above 50 years of 
age in our study, 2 out of 3 from patients above 60. This finding is also concordant 
with the results of study by Enrico et al where patients above 60 harboured most of the 
CRE isolates,71which are indicative of the vulnerability of the above 50 (especially 
postmenopausal females) age group to urinary tract infections due to multiple 
factors.73 
 
6.11 PREVALENCE OF CRE IN INPATIENTS VS OUTPATIENTS: 
In this study, most of the Carbapenemase producing Enterobacteriaceae 
isolates were isolated from inpatients (89.28%) and very less isolates were from 
outpatients (10.72%). This finding is in concordance with the study by Chaung et al 
where 70.5% of the CRE infections were acquired from hospital settings and only 
29.5% from community settings.69This result is also in concordance with the study by 
Mamta et al where more than 90% of the isolates were from inpatients and less than 
10% from outpatients67. These findings are indicative of most of the drug resistant 
infections being hospital acquired rather than community acquired and prolonged 
hospitalisation is a strong risk factor for acquision of these resistant bugs, showing the 
necessity for isolation of patients infected with drug resistant organisms, avoidance of 
irrational use of antibiotics on inpatients and strict adoption of hand hygiene measures 
like handwashing/ application of hand rub by the medical and paramedical personnels 
before handling each patient. 
6.12 PREVALENCE OF CRE IN RELATION TO WARDS IN HOSPITAL: 
In our study, Surgical ward is the ward where most CRE has been isolated (26 
out of 56 making 46.43%), followed by Medicine wards (10.71%), Chest and TB 
ward and OG ward (8.93% each), Ortho ward (7.14%), ICU and casualty (5.36% 
each), and burns and dermatology ward (3.57%) each. 
This distribution is in concordance with the study results of Gabriella et al., 
where majority of the CRE were from patients in Surgical wards constituting thirty 
percent and Intensive Care Units. This coincides with the results of Alves study, 
where the greatest isolation of about thirty two percent occurred in the surgical clinic 
and nearly the same number from internal medicine specialties. These results are also 
in concordance with a study by P k nair et al where most of the CRE isolates were 
from surgical ward, followed by ICU61. 
Klebsiella spp., is the predominant CRE from surgical wards (13/26), followed 
by E.coli(7/26) in our study. This result is in concordance with a study by Fortunata et 
al where Klebsiella spp., is the predominant CRE isolate from surgical wards.74 This 
finding is also in concordance with a study by PK Nair et al where Klebsiella spp., is 
the predominant isolate from surgical wards66. E.coli is the predominant isolate from 
medicine ward, especially from patients suffering from infections of the urinary tract 
in our study. This result is also concordant with the results of study by PK Nair et al66. 
From ICUs, E.coli, species of Klebsiella and Proteus were equally isolated in our 
study, which is similar to the study by PK Nair et al66. 
6.13COMORBID CONDITIONS & RISK FACTORS FOR CRE INFECTIONS: 
CRE from pus have been isolated from various cases like diabetic ulcer, Ileostomy 
wounds, Bed sores, surgical wounds, CKD patients, infected vulval cyst, cervicitis and 
pelvic/ gluteal abscesses. Diabetic foot is the most common clinical condition 
associated with CRE infection in this study. Type 2 diabetes mellitus [24/56(43%)] is 
the most common co morbid condition associated with CRE infected patients in this 
study which is concordant with the results of Alice et al. where Diabetes mellitus is 
the most common co-morbid condition (44.3%) associated with CRE infected 
patients59. Diabetes mellitus is as such an immunocompromised state which makes the 
patient easily susceptible to infections with drug resistant organisms. 
CKD is also another co morbid condition leading to CRE infections according to 
this study. This is in concordance with the study by Garbarti et al where CKD was the 
predominant co-morbid condition75 (48.3%). Both diabetes mellitus and chronic 
kidney disease are immunocompromised states, which show that 
immunocompromised patients are at increased risk of acquiring CRE infection. This 
finding also correlates with a study by Ling et al where diabetes mellitus, 
cardiovascular disease, renal disease and cancer were the most common co-morbid 
conditions associated with CRE infections. Recent surgery (post operative state) is 
another common risk factor in this study which also correlates with their study.76  
Hospitalisation, especially prolonged hospitalisation for more than a week has 
been identified as a risk factor in this study, as it was found that all the in-patients 
harbouring CRE isolates in their clinical samples had been hospitalised for more than 
a week. Prolonged hospitalisation is an independent risk factor for infections with 
drug resistant organism76.  
Prolonged antibiotic usage is another independent risk factor in our study, for the 
patient being infected with drug resistant CRE, as about 90% of the CRE harbouring 
patients in this study were on antibiotic treatment for more than week while in 
hospital. So irrational or overuse of antibiotics have to be avoided to prevent spread of 
drug resistant organisms76. 
E.coli is the most common isolate from patients who have undergone abdominal 
surgeries like ileostomy and laparotomy [4/6 (66.6%)] in this study. E.coli and 
Proteus spp., are the CRE isolated from two burns patients included in this study. One 
Carbapenem resistant Citrobacter spp., was isolated from Ileostomy wound. 
18/56(32.14%) of the CRE isolates were from postoperative cases in this study, 
Klebsiella spp., (50%) being the predominant isolate. This finding is concordant with 
that of an Indian study by Sunilkumar et al where postoperative patients were very 
commonly infected with Carbapenemase producing Klebsiella spp.,51 
6.14 DRUG SENSITIVITY PATTERN OF CRE IN OUR STUDY:  
In this study, most of the isolates resistant to Meropenem were resistant to all 
the routinely used drugs for AST by Kirby Bauer disc diffusion testing (AMP, COT, 
CIP, CTR, CFS, PIT and IPM). However, a few isolates were sensitive to some of the 
drugs. 2 Carbapenem resistant E.coli and 4 Carbapenem resistant Klebsiella spp., 
isolates were sensitive to Gentamycin (overall sensitivity to G was 16.1%), as 
determined the routine Kirby Bauer disc diffusion testing according to current CLSI 
guidelines. 6 E.coli, 6 Klebsiella spp.,, 1 Citrobacter spp., and 2 Proteus spp., were 
sensitive to Amikacin (overall sensitivity to AK was 26.98%). All other isolates were 
resistant to all other drugs that were tested for. The findings are similar to the results 
of a study carried out by Betina et al., where some of the isolates resistant to 
Imipenem showed sensitivity to Aminoglycosides like Gentamycin and Amikacin. 
All the Meropenem resistant isolates were found to be susceptible to 
Tigecycline and Colistin (100% each) as tested by the Kirby Bauer disc diffusion 
assay. This finding is also in concordance with the results of Betina and Radha 
Srinivasan et al. where all the Carbapenem resistant isolates were sensitive to Colistin 
and Tigecycline77. These results suggest that Colistin and Tigecycline can be used for 
the treatment of CRE infections. Though some studies have reported emerging 
resistance of gram negative bacilli to these newer drugs, extensive resistance has not 
yet occurred, and it’s time to protect these drugs from the superbugs through proper 
usage of these drugs only when they are absolutely indicated, that too as a part of 
combination therapy45.  
6.15 PHENOTYPIC TESTS: 
Among various methods of Carbapenemase and AmpC β-lactamase detection 
in Enterobacteriaceae, phenotypic methods are widely employed for routine testing 
because of their technical simplicity and cost-effectiveness. However, results of these 
phenotypic methods are essentially affected by several environmental and technical 
factors, such as, temperature, incubation period, quality and thickness of media, 
inoculums characters, distance between the antibiotic disks and subjective errors78. 
Growth on KPC chrome ager, Modified Hodge test, Ethylene diamine tetra acetic acid 
disc synergy test (EDS) and Combined disc test(CDT) for Carbapenemase detection 
& AmpC disk test for AmpC β-lactamases have been used in this study, as these tests 
were easy to perform , and they were also found to have considerable sensitivity and 
specificity as detected by previous studies.  
6.15.1 GROWTH ON KPC CHROM AGAR: 
When the isolates resistant to Meropenem were tested by KPC chrome agar, 
52/56 isolates (92.86%) grew on chrome agar with specific colours indicating 
Carbapenemase production. The isolates included 19/21 E.coli (90.48%), 23/25 
Klebsiella spp., (92%), 8/8 Proteus spp., (100%) and 2/2 Citrobacter spp., The 
remaining four CRE isolates that did not grow on KPC chrome agar might have been 
resistant to Meropenem due to mechanisms other than Carbapenemase production, 
such as porin loss, efflux of antibiotics or hyperproduction of Amp C enzymes31.KPC 
CHROM agar has a high sensitivity of 100% and specificity of 98.4% for detecting 
CRE38. In a study by Akshaya rao et al, KPC chrome agar was found to detect 
Carbapenemase production in 96.6% of CRE isolates79.  KPC, IMP, VIM, NDM, and 
OXA-48-producing CRE can be detected by KPC chrome agar38. A study by 
Nordmann et al has found that KPC chrome agar had a relatively higher sensitivity for 
detecting class A Carbapenemases (67%) and lower sensitivity for other classes - 56% 
for class B and 14% for class D41. 
6.15.2 MODIFIED HODGE TEST: 
All the 56 isolates were tested by MHT. 38(67.86%) were MHT positive and 
the remaining 18 were negative (12.14%). This result is in concordance with the study 
by Priyadharshini et al, where 82% of the CRE isolates were MHT positive80. It is also 
in concordance with the study by Pratita et al where 60% of the CRE isolates were 
MHT positive67.  
MHT positives in our study consisted of 17 (45%) Klebsiella spp., spp., 15 
(39%) E.coli, 6 (16%) Proteus spp., and no Citrobacter spp. In a study by Amjad et 
al., 38% of E.coli, 17% of  Klebsiella spp., pneumoniae (17%), 2% Citrobacter spp., 
diversus (2%) were MHT positive81. According to a study by Pratita et al, E.coli was 
the predominant organism positive for MHT67. MHT is the phenotypic confirmatory 
test for Carbapenemases according to CLSI. It is most sensitive for detection of KPC 
Carbapenemases.37 It has varying sensitivity for other types of Carbapenemases. It is 
not done as a routine, but done for epidemiological purposes37. It can also give false 
positives with ESBL and Amp C producers. PCR is the confirmatory test. With all 
these, only 70% positivity in our study may be due to the other CRE isolates 
producing non class A Carbapenemases, which can be confirmed by genotyping. 
6.15.3 EDTA DISC SYNERGY TEST: 
EDS test was performed on all 56 isolates, out of which 44(78.57%) were 
found to be positive i.e. MBL producers and 12 (21.43%) were negative i.e. the 
prevalence of MBL producing CRE according to our study was 78.57%. This finding 
is concordant with the study by Rajkumari et al where the prevalence of MBL 
producing CRE was 90%82. 
Among the 44 isolates that tested EDS test positive 15(34.09%) were 
Klebsiella spp., 19(47.5%) were E.coli, 8(20%) were Proteus spp., and 2(5%) were 
Citrobacter spp., spp., Thus E.coli was the predominant MBL producer according to 
our study. This finding is concordant with the results of the study by M Choudary et al 
,where E.coli was the predominant MBL producing CRE (37.5%) followed by 
K.pneumoniae (27.8%). NDM is the predominant MBL found in India. In a study by 
Diene et al, Klebsiella spp., was the predominant NDM producer followed by E.coli83. 
The result is also concordant with a study by Rajkumari et al where E.coli was the 
predominant MBL producer followed by Klebsiella spp.,82 
The sensitivity and specificity of EDS test to detect MBL producers are 95% 
and 92% respectively according to a study by Young et al. A study by Lee et al. has 
proved 100% sensitivity and specificity.41Many bacterial isolates that produce 
Metallobetalactamases are not detected by the MHT, but can be detected by the 
sensitive EDTA disk synergy test.41 
6.15.4 COMBINED DISC TEST (CDT): 
Out of the 56 isolates tested, 44(78.57%) were positive for MBL production as 
detected by the CDT (Combined disc test) in our study. The ability of the test to detect 
MBL producers is similar to that of EDTA disc synergy test. Anyway PCR is 
confirmatory. Behera et al. reported equal efficacy of both combined disk test and E 
test.84Among the 44 isolates that tested CDT positive 15(34.09%) were Klebsiella 
spp., spp., 19(47.5%) were E.coli, 8(20%) were Proteus spp., and 2(5%) were 
Citrobacter spp., which is similar to that detected by EDS test in our study.  
6.15.5 AMP C DISC TEST: 
Out of 56 Carbapenem resistant isolates tested, 26(46.43%) were identified as 
Amp C producers by Amp C disc test, which included 14(53.85%) Klebsiella spp., 
spp., 6(23.07) E.coli, 4(15.38%) Proteus spp., spp., and 2(3.57%) Citrobacter spp., 
spp., A study by Jennifer et al., has reported that the sensitivity and specificity of Amp 
C disc test in detection of AmpC enzymes that are encoded on plasmids are 98% and 
100% respectively85. The mechanism of Carbapenem resistance in Amp C producers 
is that Amp C production causes low influx and high efflux of the antibiotic due to 
outer membrane porin loss and efflux pump activation respectively85. 
6.16 CUMULATIVE RESULTS OF THE PHENOTYPIC TESTS OF THE CRE 
IN THIS STUDY: 
According to the phenotypic test results, E.coli is positive for all phenotypic 
tests indicating that it is a producer of all types of Carbapenemases (KPC, MBL, 
OXA) and also Amp C, which is concordant with a study by Gisele et al where E.coli 
was found to produce all types of Carbapenemases86. The proportion of E.coli 
producing Amp C is lower (28.57%) compared to other organisms. Klebsiella spp., 
and Proteus spp., are producers of all classes of Carbapenemases and are also Amp C 
producers. All Proteus spp., and Citrobacter spp., isolates were found to produce one 
or the other type of Carbapenemase by their growth on KPC chrome agar. Two 
Klebsiella isolates were found to be negative for all tests except Amp C disc test 
which implies that high grade Amp C production can result in Carbapenem resistance, 
even in the absence of Carbapenemase production. The proportion of MBL production 
was more (100%) in Proteus spp., and Citrobacter spp., when compared to Klebsiella 
and Escherichia isolates. The proportion of Ambler class C production was highest in 
Citrobacter spp., (2/2) followed by Klebsiella spp.,, Proteus spp., and E.coli in that 
order. Klebsiella pneumoniae is the most common Carbapenemase producer 
altogether (25/56 isolates), followed by E.coli (21/56), Proteus spp., (8/56) and 
Citrobacter spp., (2/56). This may be attributed to the rapid plasmid mediated transfer 
of resistant genes in Klebsiella.10 
Growth on KPC chrome agar and Modified Hodge test have picked up 92.86% 
and 67.86% of the CRE isolates respectively as Carbapenemase producers. EDS test 
and combined disc test, both have picked the same 78.57% of the isolates as 
Carbapenemase producers. These findings show that Modified Hodge test is the least 
sensitive and growth on CHROME agar KPC is the most sensitive for the detection of 
Carbapenemases. EDS test and CDT both have the same sensitivity as detected by our 
study. Both these tests have a higher sensitivity than Modified Hodge test and a lower 
sensitivity than CHROME agar KPC for the detection of Carbapenemases. This 
finding is concordant with the study results of Aparna et al 87. 
6.17 PREVALENCE OF THE TARGET GENES (blaNDM-1 and blaOXA-51) IN THE 
CRE ISOLATES IN THIS STUDY: 
The target genes in this study were blaNDM-1 and blaOXA-51. 21 out of 25 (84%) 
tested CRE isolates were found positive for atleast one of the target genes. Twenty out 
of 25 (80%) were found positive for blaNDM-1 gene and 8(40%) were positive for 
blaOXA-51 gene. 7(28%) for both the genes, i.e. 28% were co-producers of 
Metallobetalactamase and Oxacillinase. 13(52%) were found positive for blaNDM-1 
alone and blaOXA-51 negative. 1(4%) was found positive for blaOXA-51 alone and was 
blaNDM-1 negative. In a study published in 2016 by Mubin et al, the target genes were 
detected in 88% of the CRE isolates,  the prevalence of blaNDM were 62.5%, the 
prevalence of blaOXA were 12% and the prevalence of isolates harbouring both blaNDM 
and blaOXA were 31.8%. In a study by Jyothi et al conducted in Bangalore and 
published in 2014, the prevalence of NDM-1 producers was 93.24% (69 of the total of 
74 MDR isolates) 88. The result of our study is almost similar to the results of these 
two studies with only slight variations. 
11 out of 16(68.75%) Klebsiella spp., 7 out of 7 E.coli (100%) and 2 out of 2 
Proteus spp., that were tested were found positive for blaNDM-1. The result of this study 
is in concordance with a study by Chandran et al in 2012, conducted in Bangalore, 
where 75% of the Klebsiella spp.,isolates were NDM positive.89 It is also in 
concordance with an Indian study by Bora et al published in 2013, where all the 14 
E.coli isolates (100%) tested for blaNDM were found to be positive.90 Majority of the 
NDM producing isolates were Klebsiella spp., and E.coli, which is also in 
concordance with the study by Bora et al.90 
6.18 COMPARISON OF THE PHENOTYPIC TEST RESULTS WITH 
GENOTYPIC TEST RESULTS: 
All the isolates that were found to be positive for blaNDM-1 by genotyping were 
found positive for EDS test and CDT. This shows that EDS and CDT are 100% 
sensitive for the detection of Metallobetalactamses. And all the isolates that tested 
negative by the phenotypic EDS test and CDT also tested negative for blaNDM-1 gene 
by genotyping. This shows that EDS and CDT are 100% specific. A study by Lee et 
al. has also proved 100% sensitivity and specificity for EDS test. In a study by Jyothi 
et al, CDT detected more than 97% of the NDM-1 producers91. All these results prove 
EDS test and CDT to be the two most reliable phenotypic tests for detection of 
Metallobetalactamase producers. 
All the CRE isolates that were found to harbour NDM-1 or OXA-51 were 
found positive for growth on KPC chrome agar. So this study shows that KPC 
CHROME agar is highly efficient in detecting NDM-1 and OXA-51 producers. A 
study by Samra et al in 2008 has proved KPC chrome agar to be 100 % sensitive and 
98% specific for detection of Carbapenemases.38 
All the 8 CRE isolates confirmed as blaOXA-51 gene positive by genotyping in 
our study were found MHT positive, which shows that MHT has 100% sensitivity for 
picking up Oxacillinase producers. 14 out of 20(70%) blaNDM-1 positive isolates 
confirmed by genotyping were found positive for MHT. Thus the sensitivity of MHT 
for detection of NDM according to this study is 70%. However, 7 out of 14 isolates 
were found to be positive for both blaNDM-1 and bla OXA-51 genes, making the 
specificity of MHT for Metallobetalactamase detection doubtful, as the MHT 
positivity in those 7 isolates might have been due to Oxacillinase production and may 
not be due to Metallobetalactamase alone. In a study by Jyothi et al conducted in 
Bangalore, published in 2014, 76.47% of Metallobetalactamase producers were 
identified by MHT91, which is concordant with our results. 
blaNDM-1  gene is the one that encodes for NewDelhi Metallobetalactamase-1. It 
may either be located on chromosomes or on plasmids. If it is located on plasmid, the 
gene can carry many other resistance determining genes (upto 14) making the bacteria 
resistant to other group antibiotics in addition to being Carbapenem resistant.91This 
can result in the strain becoming multidrug resistant and even extremely drug 
resistant. The ability of these plasmid encoded resistant genes to be transferred to 
other bacteria adds fuel to the fire, making the condition even more worse because of 
rapid spread of resistance.91This explains why the Bacterial isolates resistant to 
Carbapenems in our study has been non susceptible to many other groups of drugs 
too. 
NewDelhi metallobetalactamses are reported in larger numbers in India and 
across the world. 91 This study was therefore conducted to detect the prevalence of 
Carbapenemase producers among the members of Enterobacteriaceae harbouring 
blaNDM-1 gene among the isolates that were Carbapenem resistant from a rural tertiary 
care centre in Trichy district in Tamilnadu. A high prevalence (80%) of NDM-1 
among the Carbapenemase producing isolates have been identified here, and most of 
the isolates were also found to be multidrug resistant, i.e. resistant to more than three 
groups of antimicrobials.92 
In our study, 40% (8 out of 25) of the isolates were positive for blaOXA-51 gene. 
In a study by Niu et al conducted in China, published in 2015, blaOXA-51 was identified 
in all the 93(100%) Acinetobacter isolates.93 A study by Budak et al suggests blaOXA-51 
gene to be intrinsic to Acinetobacter baumanii and a patient with Ventilator associated 
pneumonia harbouring blaOXA-51 gene in Klebsiella pneumoniae has been reported in 
their study. The reason for blaOXA-51 gene in that Klebsiella isolate was suspected to be 
chromosomal or plasmid mediated transfer from Acinetobacter, as the patient was also 
found to be infected with Acinetobacter, for which he was treated with antibiotics. 
However, PCR and other conjugation experiments proved their suspicion false.94The 
reason behind the Klebsiella pneumoniae harbouring blaOXA-51 remains obscure. In a 
study by Tolman et al in India in 2005, all the Acinetobacter isolates (100%) tested 
were found to harbour blaOXA-51 gene. In a study by Leski et al, in Sierra Leone 
blaOXA51 like gene was detected in 3/22(13.64%) Klebsiella pneumoniae isolates, 
3/22(13.64%) Enterobacter cloacae isolates and 1 E.coli (4.5%) isolate suggesting 
that the gene is no longer confined to Acinetobacter alone95. Though there are a 
considerable number of studies on blaOXA-51 in Acinetobacter in India, there are hardly 
any studies on blaOXA-51 in Enterobacteriaceae in India, and that is the reason why 
molecular detection of blaOXA-51 gene has been carried out in this study. 
With all these results, it is obvious that Carbapenemase producing 
Enterobacteriaceae are prevalent in our setting, as shown by 13 NDM-1 
Carbapenemase producers and one OXA-51 Carbapenemase producer and seven of 
the CRE isolates being producers of more than one type of Carbapenemases as 
detected by this study.  
7. SUMMARY 
This study entitled, “PREVALENCE, PHENOTYPING AND MOLECULAR 
DETECTION OF blaNDM-1 and blaOXA-51 GENES IN CARBAPENEMASE 
PRODUCING STRAINS AMONG THE CARBAPENEM RESISTANT 
ENTEROBACTERIACEAE” , was carried out in the department of Microbiology, 
Chennai medical college hospital and research centre, Trichy from October 2014 to 
December 2015. 
 Over a period of fifteen months (October 2014 to December 2015), the 
laboratory received 6651 heterogenous clinical samples, from which 
2038(30.6%) gram negative bacilli were isolated. 
 Among the gram negative isolates, Enterobacteriaceae constituted 69.72% (N= 
1421) 
 The Enterobacteriaceae were isolated predominantly from pus samples 
(41.4%), followed by urine (33.9%), sputum (20.1%), blood (2.4%) and body 
fluids (2.2%). 
 Of the Enterobacteriaceae isolates (1421), 56 were found to be Carbapenem 
resistant as identified by the disc diffusion assay and thus the prevalence of 
CRE by this method was 3.94%. 
 Further analysis of these CRE in relation to clinical samples revealed that it 
was 71.43% (N=40) from pus, 19.64 % (N=11) from sputum and 8.73% (N=5) 
from urine. There were no Carbapenem resistant isolates from blood or other 
body fluids. 
 The prevalence in relation to gender showed that CRE isolates were more in 
males (62.5%) and it was statistically significant. 
 Males above 60 years of age were predominantly infected with CRE (37.5%) 
and diabetes mellitus was the most common co-morbid condition (42.86%) 
associated with CRE infections. Most of the CRE were isolated from patients 
admitted to surgical wards (71.43%). 
 The antimicrobial sensitivity of the 56 CRE isolates to Gentamycin, Amikacin, 
Cefotaxime, Tigecycline and Colistin were in the order of 16.1, 26.8, 53.6, 100 
and 100% respectively. These 56 strains were resistant to Ampicillin, 
Fluroquinolones, betalactam-betalactamase inhibitors. 
 All the 56 CRE were subjected to various phenotypic tests which included 
growth on KPC CHROM agar, Modified Hodge test, EDTA disc synergy test, 
Combined disc test and AmpC disc test.  
 Among the five phenotypic tests used, the highest number of CRE(52/56 – 
92.86%) were detected  by KPC CHROM agar followed by Combined disc and 
EDTA disc synergy tests in equal numbers (44/56 – 78.57%), and the least 
detected by Modified Hodge test (38/56 – 67.86%). AmpC disc test detected 
(30/56-53.57%) of CRE isolates as AmpC producers. 
 Out of 56 CRE, 25 belonging to odd numbers were subjected to genotyping of 
blaNDM-1 and blaOXA-51 genes. The analysis revealed that 7 were positive for 
both, 13 others for blaNDM-1 and one other for blaOXA-51 alone. 
 Comparative analysis of phenotyping and genotyping carried out for 25 CRE 
revealed that all the five phenotypic tests were positive only for one isolate 
(Proteus spp.,) which carried both the genes. All the 21 isolates which were 
positive for blaNDM-1 genes were also positive for growth on KPC CHROM 
agar, EDS test, CDT, showing that these three phenotypic tests are 100% 
efficient in detecting NDM. The 4 isolates blaNDM-1 negative isolates were 
negative for EDS test and CDT, showing these two tests to have 100% 
specificity as well in detecting NDM. 
 Comparative analysis of phenotyping and genotyping carried out for 25 CRE 
revealed that all the five phenotypic tests were positive only for one isolate 
(Proteus spp.,) which carried both the genes. A good correlation has been 
obtained between the phenotypic and genotypic tests suggesting the use of 
easier and cost effective phenotypic tests for routine detection of 
Carbapenemase producers, which can aid to a great extent in correct diagnosis 
and treatment patients infected with Carbapenemase producers. However, one 
has to rely on independent genotyping and subtyping to recognise molecular 
epidemiology towards the surveillance and prevention.  
 
 
 
 
 
 
 
8. CONCLUSION 
 In the present study, 1421 Enterobacteriaceae were isolated from 6651 
heterogenous clinical samples. 
 56 of these 1421 were found to be resistant to Carbapenem by disc diffusion 
assay. Thus disc diffusion identified a prevalence of 3.94% as presumptive 
Carbapenemase producers. 
 These CRE were isolated in more numbers from pus than from other biological 
samples. The CRE were predominant in males and were more in surgical 
wards. 
 All these were resistant to commonly used antimicrobial agents like 
Ampicillin, Betalactam-betalactamase inhibitor combinations and 
Fluoroquinolones. 
 Phenotypic tests performed on these 56 isolates with growth on KPC CHROM 
agar, MHT, EDS, CDT and Amp C disc tests revealed positivity in 92.86, 
67.86, 78.6, 78.6 and 53.6% respectively indicating the ability of different 
phenotypic tests to detect different betalactamase enzymes depending on the 
biological properties of the isolates producing them. 
 Twenty five of the 56 odd numbered CRE isolates were subjected to multiplex 
PCR for detection of blaNDM-1 and blaOXA-51 genes. 7 were found to carry both 
the genes, 13 with NDM gene alone and 1 with OXA gene alone. 
 All the 20 blaNDM-1 gene positive isolates were found to test positive for 
growth on KPC CHROM agar, EDS and CDT which suggests that KPC 
CHROM agar, EDS and CDT are highly efficient in detecting NDM producers. 
All the 5 isolates which were negative for EDS and CDT were also negative for 
blaNDM-1 gene, suggesting that the EDS and CDT can rule out NDM non 
producers rightly. In the present study blaOXA-51 was noticed among 8 of the 25 
(40%) isolates. All these 8 isolates were found to be positive for MHT and 
growth on KPC, suggesting that MHT and KPC are highly efficient in 
detecting OXA producers. This makes one to consider the use of simple 
phenotypic methods in resource limited centres/ laboratories to aid in the 
diagnosis of the Carbapenemase producing Enterobacteriaceae. 
 Inter relationship between the phenotypic and genotypic tests when analysed 
showed that the consistency between the two were considerably good. 
However, genotyping is the gold standard method for detecting the specific 
resistance determining genes which is required in subtyping in molecular 
epidemiology, surveillance system and recognition of transmission of resistant 
strains from one area to another. 
 The prevalence of CRE in our setting is considerably low, probably due the 
rural population that is relatively naive to antibiotics. Even then, the presence 
of these superbugs itself strongly suggests the need to prevent their further 
spread, which can be done by appropriate use of antibiotics only when truly 
needed, appropriate hand hygiene measures, health education of the patients 
regarding strict compliance to prescribed antibiotic regimen and to avoid over 
the counter antibiotics, upto date vaccinations, proper handling of food and 
water, isolation of patients carrying drug resistant organisms. All these 
measures can prevent us from reaching the post antibiotic era where common 
diseases can kill us once again. Carrying out researches/studies on drug 
resistant organisms, formulation of antibiotic policies for health institutions and 
Antibiotic stewardship programs can aid to a great extent in proper antibiotic 
usage and prevention of further spread of resistance, thereby paving a way for a 
healthy community. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
STRENGTH OF THE STUDY: 
 Five phenotypic tests on CRE have been compared and analysed. 
 Clinical correlation has been done with respect to parameters like age, gender, 
inpatient/outpatient details and co-morbid conditions. 
 Genotyping for the most common (blaNDM-1) and one uncommon gene 
(blaOXA-51) has been carried out. 
 Genotyping results have been compared to the phenotyping results and the 
efficacy of each test has been analysed. 
LIMITATIONS OF THE STUDY: 
 Test sample size is low 
 Genotyping has been done only for 25 out of the 56 CRE isolates. 
 It is a single centre based study. 
 
 
 
 
 
 
 
 
MASTER CHART: 
Table showing Patient details, bacterial isolate and their drug sensitivity pattern 
PUS ISOLATES: 
S 
No 
IP no Age Sex Ward Diagnosis Comorb
id 
conditio
n 
Organism G A
M
P 
C
O
T 
C
I
P 
C
T
X 
C
F
S 
C
X 
A
K 
A
T 
M
R
P 
K
P
C 
M
H
T 
E
D
S 
C
D
T 
A
MP 
C  
bla 
ND
M-
1 
Bla 
OX
A-
51 
Clinical 
condition 
1 1646
64 
38 M Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R R S R R + + - - + N P Improved 
2 1634
69 
45 F OG TAH/BS
O 
- Klebsiella 
spp. 
S R R R R R R R R R + - - - - ND ND Improved 
3 1614
65 
75 M Surgery Ileostomy  T2 DM E.coli R R R R R R R R R R + - + + - ND ND Improved 
4 1645
78 
70 M Surgery Diabetic 
foot  
T2 DM Klebsiella 
spp. 
R R R R R R S R R R + + + + - P P Improved 
5 1646
72 
77 M Derm Bed sores T2 DM Klebsiella 
spp. 
R R R R R R S S R R + + + + - P P Expired 
6 1646
64 
38 M Surgery Diabetic 
foot 
T2 DM Proteus spp R R R R R R S S R R + + + + + ND ND Improved 
7 1620
02 
55 M Ortho AK 
amputatio
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + - - - + ND ND Improved 
n 
8 1645
78 
70 M Surgery Diabetic 
foot 
T2 DM Proteus spp R R R R R R S R R R + - + + - P N Improved 
9 1638
59 
50 M ICU CKD T2 DM E.coli R R R R R R R R R R - - - - - ND ND Improved 
10 1630
07 
40 F OG TAH - E.coli R R R R R R S R R R + + + + - P N Improved 
11 1635
66 
52 F Surgery Diabetic 
foot 
T2 DM E.coli R R R R R R S S R R + - + + + P N Improved 
12 1605
49 
38 M Medicine Pressure 
sore 
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + + - - + ND ND Improved 
13 1640
75 
37 F OG Infected 
vulval 
cyst 
- Klebsiella 
spp. 
R R R R R R S R R R + + + + - P N Improved 
14 1616
71 
56 M Ortho ORIF, 
Locking 
plate 
- E.coli S R R R R R R R R R + + + + + ND ND Improved 
15 1626
88 
65 M Surgery Laparoto
my 
- E.coli R R R R R R R R R R + + + + - ND ND Improved 
16 1611
30 
55 M Surgery Iliostomy - Klebsiella 
spp. 
R R R R R R S R R R + + + + - P P Improved 
17 1611
30 
55 M Surgery Iliostomy - Citrobacter 
spp  
R R R R R R R R R R + - + + + ND ND Improved 
18 1154
47 
55 M Casualty Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + - + + + ND ND Improved 
19 5029
54 
54 M Casualty Diabetic 
foot 
T2 DM E.coli R R R R R R S S R R + + + + - P P Improved 
20 1132
061 
55 F OG Chronic 
cervicitis 
- E.coli R R R R R R S S R R + - + + + P N Improved 
21 1628
29 
65 M Surgery Wound 
debridem
ent 
T2 DM E.coli S R R R R R S R R R + + + + - P N Improved 
22 1624
42 
53 M Surgery Diabetic 
foot 
T2 DM Proteus spp R R R R R R S R R R + + + + + P P Improved 
23 1622
30 
54 M Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
S R R R R R R R R R + + - - + ND ND Improved 
24 1626
23 
65 M Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R S S R R - + - - + N N Improved 
25 1624
58 
48 F Surgery Diabetic 
foot 
T2 DM Proteus spp R R R R R R R R R R + + + + + ND ND Improved 
26 1623
22 
64 F Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R S S R R - - - - + N N Improved 
27 1620
14 
45 M Surgery Pyocele 
R- 
orchidect
omy 
- Citrobacter 
spp 
R R R R R R R S R R + - + + + ND ND Improved 
28 1612
32 
61 M Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + + + + - P N Improved 
29 1604
04 
75 M Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + + + + - P N Improved 
30 1597
63 
68 F Surgery Abscess-
both 
Thigh 
T2 DM Klebsiella 
spp. 
S R R R R R R R R R + + + + + ND ND Improved 
31 1605
92 
70 M Surgery R Gluteal 
abscess 
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + + - - + ND ND Improved 
32 1026
388 
35 F OG Pelvic 
abscess 
- E.coli R R R R R R S S R R + + + + - P N Improved 
33 1581
41 
57 M Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R S R R R + + + + - P N Improved 
34 1605
02 
25 M Ortho Wound 
debridem
ent with 
EF 
- Klebsiella 
spp. 
R R R R R R R R R R + - + + + P N Improved 
35 1614
31 
40 F Surgery Diabetic 
foot 
T2 DM Klebsiella 
spp. 
R R R R R R R R R R + - + + + P N Improved 
36 1612
98 
43 F Burns 40% 
burns 
- E.coli R R R R R R S R R R + - + + + ND ND Improved 
37 1578
28 
28 F Burns 45% 
burns 
- Proteus spp R R R R R R R S R R + + + + - P P Improved 
38 1609
68 
60 M Medicine R- sided 
empyema 
- Klebsiella 
spp. 
R R R R R R R R R R + + + + - P P Improved 
39 1591
19 
51 M Surgery Cholecyst
ectomy 
- E.coli R R R R R R S R R R + + + + - ND ND Improved 
40 1587
42 
44 F Derm Psoriasis 
vulgaris 
- E.coli R R R R R R R R R R + + + + - ND ND Improved 
 
URINARY ISOLATES: 
S 
No 
IP no Ag
e 
S
ex 
Ward Diag
nosis 
Catherised / 
Not 
Organism G A
M
P 
C
O
T 
C
I
P 
C
T
X 
C
F
S 
C
X 
A
K 
A
T 
N
I
T 
M
R
P 
K
P
C 
M
H
T 
E
D
S 
C
D
T 
A
M
P 
C 
bla 
ND
M-
1 
bla 
OX
A-
51 
Clinical 
condition 
1 193461 32 F Orth
o 
ORI
F 
Catheterisd E.coli R R R R R R S S R R R + + + + - ND ND Improved 
2 221220 56 F Medi
cine 
CRF Uncatheteris
ed 
E.coli R R R R R R S R R R R + + + + - ND ND Improved 
3 214028 20 M Surg
ery 
Wou
nd 
debri
deme
nt 
Catheterised Klebsiella spp. R R R R R R S S R R R + + + + - ND ND Improved 
4 215254 64 F ICU CA 
palat
Catheterised Proteus spp R R R R R R R R R R R + - + + + ND ND Improved 
e 
5 214211 65 M ICU MI 
infar
cts 
Catheterised Klebsiella spp R R R R R R S R R R R + + - - + ND ND Improved 
 
 
SPUTUM 
S 
N
o 
IP 
no 
Ag
e 
S
e
x 
W
ard 
Diagn
osis 
Com
orbi
d 
cond
ition 
Organism G A
M
P 
C
O
T 
C
I
P 
C
T
X 
C
F
S 
C
X 
A
K 
A
T 
MR
P 
KPC MHT EDS CDT AMP 
C 
bla 
NDM-1 
bla 
OXA-51 
Clinical 
condition 
1 205
371 
85 M CT
B 
Pneu
monia 
Post 
PT 
Klebsiella 
spp. 
R R R R R R R R R R - - - - + N N Improved 
2 204
021 
68 M CT
B 
Ascite
s 
- E.coli R R R R R R S S R R + + + + - ND ND Improved 
3 203
156 
68 M Su
rge
ry 
Multip
le 
liver 
absces
s 
- E.coli R R R R R R S R R R + + + + - ND ND Improved 
4 207
085 
55 M cas
ual
ty 
? PT - Proteus 
spp 
R R R R R R S R R R + + + + - ND ND Improved 
5 204
098 
60 M CT
B 
DCLD PT Klebsiella 
spp. 
S R R R R R S S R R + + + + - ND ND Improved 
6 207
767 
55 M Su
rge
ry 
RIF 
mass/ 
COPD 
- E.coli R R R R R R S R R R + - + + + ND ND Improved 
7 206
221 
74 F Me
dic
ine 
LRI/C
AD 
SHT
N 
E.coli R R R R R R S S R R + + + + - ND ND Improved 
8 203
364 
55 F Me
dic
ine 
Bronc
hitis 
 E.coli R R R R R R R R R R + + - - + N N Improved 
9 205
381 
60 M CT
B 
LRI Post 
PT 
Klebsiella 
spp. 
R R R R R R S R R R + - + + + P N Improved 
1
0 
204
240 
68 M CT
B 
?PT - Proteus 
spp 
R R R R R R R R R R + + + + - ND ND Improved 
1
1 
206
221 
74 F Me
dic
ine 
DCLD - E.coli R R R R R R S R R R + + + + - ND ND Improved 
 
*-Only 25 isolates were subjected to genotyping. ND (Not done) indicates that the isolate has not been subjected to genotyping. 
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CLINICAL DETAILS: 
 
NAME:                                                                                                       AGE/SEX:                                                                                                            
 
S.No:                                                                                                           IP/OP NO: 
                                                                                                                                      
            
                   D.O.A:  
ADDRESS:                                                                                                  D.O.D:  
OCCUPATION:  
 
PRESENTING COMPLAINTS (WITH ANTIBIOTIC HISTORY):  
 
PAST HISTORY:  
Hospitalisation  
 
Treatment  
 
Invasive procedure if any 
 
   
  
HISTORY OF ASSOCIATED ILLNESS: Diabetes/HIV/other co-morbid conditions  
 
GENERAL PHYSICAL EXAMINATION:  
 
PROVISIONAL DIAGNOSIS:  
 
TREATMENT  
 
INVESTIGATIONS DONE:  
A) GENERAL:  
 
B) MICROBIOLOGY: 
     Sample, date and site of collection:   
               
 
Culture:                                                                                  Gram Stain:  
 
    Nutrient agar: 
 
    Blood agar: 
 
    Mac Conkey agar: 
 
    Chocolate agar: 
     
  
 
 
Organism isolated: 
 
ANTIBIOGRAM: 
 Antibiotic  Zone  Interpretation 
G   
Amp   
COT   
CIP   
CTX   
CFS   
CX   
AK   
AT   
MRP   
 
Patient’s response to treatment:  
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PIGMENT 
 
 
CATALASE 
 
 
OXIDASE 
 
 
MOTILITY 
 
 
INDOLE 
 
 
UREASE 
 
 
NR TEST 
 
 
MR TEST  
VP TEST  
Glucose  
Lactose  
Sucrose  
Maltose  
Mannose  
Xylose  
Lysine  
Arginine  
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